busulfan has been researched along with Dysmyelopoietic Syndromes in 176 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this prospective study 60 patients of median age 46 (range: 5-60 years), with acute myelogenous leukemia (AML; n = 44), acute lymphoblastic leukemia (ALL; n = 3), or myelodysplastic syndrome (MDS; n = 13) were conditioned for allogeneic hematopoietic cell transplantation with a treosulfan/fludarabine (Flu) combination." | 9.15 | Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies. ( Appelbaum, FR; Bedalov, A; Deeg, HJ; Doney, KC; Flowers, ME; Guthrie, KA; Hilger, RA; Kovacsovics, TJ; Maziarz, RT; Nemecek, ER; Pagel, JM; Sanders, JE; Scott, BL; Sickle, EJ; Sorror, ML; Witherspoon, R; Wood, BL; Woolfrey, AE, 2011) |
| "A total of 45 patients with primary myelodysplastic syndromes were conditioned with 3×14 g/m(2) treosulfan and 5×30 mg/m(2) fludarabine followed by allogeneic hematopoietic stem cell transplantation." | 9.15 | Reduced-toxicity conditioning with treosulfan and fludarabine in allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes: final results of an international prospective phase II trial. ( Baumgart, J; Beelen, DW; Blau, IW; Casper, J; Einsele, H; Finke, J; Freund, M; Giebel, S; Gramatzki, M; Holowiecki, J; Kienast, J; Larsson, K; Markiewicz, M; Mylius, HA; Pichlmeier, U; Repp, R; Ruutu, T; Schnitzler, M; Stelljes, M; Stuhler, G; Trenschel, R; Uharek, L; Volin, L; Zander, AR, 2011) |
| "To reduce the incidence of graft-versus-host disease (GVHD), we added Thymoglobulin (THY) to dose-adjusted oral busulfan plus cyclophosphamide (targeted BUCY)." | 9.12 | Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen. ( Anasetti, C; Appelbaum, FR; Boeckh, M; Deeg, HJ; Doney, KC; Flowers, ME; Hansen, JA; Heimfeld, S; Kiem, HP; Martin, PJ; McCune, JS; Myerson, D; Nash, RA; O'Donnell, PV; Radich, JP; Sandmaier, BM; Scott, BL; Sorror, ML; Storb, R; Storer, BE; Warren, EH; Witherspoon, RP; Woolfrey, A, 2006) |
| "Sixty-two adults underwent marrow or blood stem cell transplantation from an HLA-matched related donor using high-dose thiotepa, busulfan, and cyclophosphamide (TBC) as the preparative regimen for treatment of advanced myelodysplastic syndrome (MDS) (refractory anemia with excess blasts with or without transformation) or acute myelogenous leukemia (AML) past first remission." | 9.09 | Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia. ( Abi-Said, D; Anderlini, P; Andersson, BS; Andreeff, M; Bibawi, S; Braunschweig, I; Champlin, R; Claxton, D; Donato, M; Estey, EH; Fayad, L; Gajewski, J; Giralt, S; Khouri, I; Mehra, R; Przepiorka, D; Ueno, NT; van Besien, K, 2001) |
| " We therefore assessed 83 patients (age, 16-70 years): 68 with acute leukemia (including 34 in remission and 34 with refractory disease) and 15 patients with myelodysplastic syndrome, in HCT trials using RIC with busulfan, fludarabine, and antithymocyte globulin." | 7.77 | Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome. ( Hwang, HJ; Jeon, M; Jung, AR; Kang, YA; Kim, DY; Kim, SH; Lee, JH; Lee, KH; Lee, YS; Seol, M; Shin, HJ; Yun, SC, 2011) |
| "Busulfan (Bu)-based preparative regimens have not been extensively investigated in Hodgkin disease (HD)." | 7.73 | Long-term outcome of Hodgkin disease patients following high-dose busulfan, etoposide, cyclophosphamide, and autologous stem cell transplantation. ( Andrèsen, S; Avalos, B; Bolwell, B; Copelan, E; Elder, P; Farag, S; Kalaycio, M; Lin, T; Marcucci, G; Penza, S; Pohlman, B; Sobecks, R; Wadehra, N, 2006) |
| "Eighty-three patients with various chronic myeloproliferative disorders [polycythemia vera (PV), essential thrombocytosis (ET), idiopathic myelofibrosis (IMF)] were analyzed for the occurrence of acute myeloid leukemia (AML) and myelodysplasia (MDS) during treatment with hydroxyurea (HU) alone or HU following treatment with busulphan (BU)." | 7.72 | Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan. ( Hasselbalch, HC; Nielsen, I, 2003) |
| " We reviewed our experience using busulfan and cyclophosphamide (CY), instead of TBI, as the preparative regimen for allogeneic BMT to study the incidence and relationship to graft-versus-host disease (GVHD) of post-treatment eosinophilia." | 7.69 | Eosinophilia after allogeneic bone marrow transplantation using the busulfan and cyclophosphamide preparative regimen. ( Bolwell, BJ; Kalaycioglu, ME, 1994) |
| "Preparative regimens containing busulfan (BU) followed by allogeneic bone marrow transplantation (BMT) were used in 27 consecutive patients with myelodysplastic syndromes (MDS)." | 7.68 | Busulfan-based regimens and allogeneic bone marrow transplantation in patients with myelodysplastic syndromes. ( Cronin, S; Dan, ME; de Planque, MM; Hussein, M; Karanes, C; Lum, LG; Mohamed, A; Ratanatharathorn, V; Schultz, KR; Uberti, J, 1993) |
| "Clofarabine has potent antileukemia activity and its inclusion in reduced-intensity conditioning (RIC) allogeneic hematopoietic stem cell transplantation (HSCT) for acute leukemia could potentially improve outcomes." | 6.82 | Phase II Trial of Reduced-Intensity Busulfan/Clofarabine Conditioning with Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Acute Myeloid Leukemia, Myelodysplastic Syndromes, and Acute Lymphoid Leukemia. ( Alyea, E; Ballen, KK; Chen, YB; Cutler, C; Dey, BR; Driscoll, J; El-Jawahri, A; Ho, VT; Hunnewell, C; Li, S; McAfee, SL; Poliquin, C; Saylor, M; Soiffer, RJ; Spitzer, TR, 2016) |
| "Busulfan is a commonly used chemotherapeutic agent in myeloablative conditioning regimens for allogeneic hematopoietic cell transplantation (allo-HCT)." | 5.42 | Subacute hepatic necrosis mimicking veno-occlusive disease in a patient with HFE H63D homozygosity after allogeneic hematopoietic cell transplantation with busulfan conditioning. ( Boyer, MW; Chen, S; Chen, X; Hildebrandt, GC; McDonald, GB; Osborn, JD, 2015) |
| "Diagnosis at time of presentation was refractory anemia with excess of blasts (RAEB) in two patients, RAEB in transformation (RAEB-t) in three, and juvenile chronic myelogenous leukemia (JCML, the pediatric counterpart of adult chronic myelomonocytic leukemia) in the remaining three children." | 5.29 | Busulfan, cyclophosphamide and melphalan as conditioning regimen for bone marrow transplantation in children with myelodysplastic syndromes. ( Bonetti, F; Cazzola, M; Locatelli, F; Maserati, E; Paolucci, P; Pedrazzoli, P; Pession, A; Prete, A; Prete, L; Zecca, M, 1994) |
| "In this prospective study 60 patients of median age 46 (range: 5-60 years), with acute myelogenous leukemia (AML; n = 44), acute lymphoblastic leukemia (ALL; n = 3), or myelodysplastic syndrome (MDS; n = 13) were conditioned for allogeneic hematopoietic cell transplantation with a treosulfan/fludarabine (Flu) combination." | 5.15 | Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies. ( Appelbaum, FR; Bedalov, A; Deeg, HJ; Doney, KC; Flowers, ME; Guthrie, KA; Hilger, RA; Kovacsovics, TJ; Maziarz, RT; Nemecek, ER; Pagel, JM; Sanders, JE; Scott, BL; Sickle, EJ; Sorror, ML; Witherspoon, R; Wood, BL; Woolfrey, AE, 2011) |
| "A total of 45 patients with primary myelodysplastic syndromes were conditioned with 3×14 g/m(2) treosulfan and 5×30 mg/m(2) fludarabine followed by allogeneic hematopoietic stem cell transplantation." | 5.15 | Reduced-toxicity conditioning with treosulfan and fludarabine in allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes: final results of an international prospective phase II trial. ( Baumgart, J; Beelen, DW; Blau, IW; Casper, J; Einsele, H; Finke, J; Freund, M; Giebel, S; Gramatzki, M; Holowiecki, J; Kienast, J; Larsson, K; Markiewicz, M; Mylius, HA; Pichlmeier, U; Repp, R; Ruutu, T; Schnitzler, M; Stelljes, M; Stuhler, G; Trenschel, R; Uharek, L; Volin, L; Zander, AR, 2011) |
| " To account for improved supportive care and other unidentified factors that may affect outcome ("period" effects), 78 acute myelogenous leukemia (AML) patients receiving Melphalan-Flu (MF), treated in parallel during this time (1997-2004) were used to estimate the period effect." | 5.13 | Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS. ( Andersson, BS; Champlin, RE; Couriel, D; de Lima, M; Giralt, S; Jones, RB; Korbling, M; Pierre, B; Roberson, S; Russell, JA; Shpall, EJ; Thall, PF; Wang, X, 2008) |
| "In the current study, we have analyzed the efficacy of cyclosporine A (CSA) plus mycophenolate mofetil (MMF) as graft-versus-host disease (GVHD) prophylaxis in the fludarabine plus melphalan or busulfan reduced intensity regimen (RIC) setting in a series of 44 patients receiving allogeneic transplantation from an unrelated donor." | 5.13 | Reduced-intensity conditioning allogeneic transplantation from unrelated donors: evaluation of mycophenolate mofetil plus cyclosporin A as graft-versus-host disease prophylaxis. ( Caballero, D; Calvo, MV; de la Cámara, R; de Oteiza, JP; Heras, I; Martino, R; Pérez-Simón, JA; Rebollo, N; San Miguel, JF; Sierra, J; Valcarcel, D, 2008) |
| " Cyclosporine alone or cyclosporine with short-term methotrexate was randomized for graft-versus-host disease prophylaxis." | 5.12 | Prospective phase II trial to evaluate the complications and kinetics of chimerism induction following allogeneic hematopoietic stem cell transplantation with fludarabine and busulfan. ( Hara, M; Hino, M; Hori, A; Kami, M; Kanda, Y; Kim, SW; Mineishi, S; Mori, S; Ohashi, Y; Saito, AM; Suzuki, R; Takami, A; Takaue, Y; Takemoto, Y; Taniguchi, S; Yamaguchi, M; Yoshida, T, 2007) |
| " Using conditioning consisting of fludarabine, busulfan, and anti-T-lymphocyte globulin and GVHD prophylaxis consisting of tacrolimus and methylprednisolone (1 mg/kg/day), 26 patients who had hematologic malignancies in an advanced stage or with a poor prognosis underwent transplantation using peripheral blood stem cells from an HLA-haploidentical donor (2-3 antigen mismatches in the graft-versus-host [GVH] direction) without T-cell depletion." | 5.12 | Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) stem cell transplantation using nonmyeloablative conditioning. ( Fujioka, T; Hasei, H; Ikegame, K; Inoue, T; Kaida, K; Kawakami, M; Kawase, I; Kim, EH; Masuda, T; Ogawa, H; Taniguchi, Y; Yoshihara, S, 2006) |
| "To reduce the incidence of graft-versus-host disease (GVHD), we added Thymoglobulin (THY) to dose-adjusted oral busulfan plus cyclophosphamide (targeted BUCY)." | 5.12 | Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen. ( Anasetti, C; Appelbaum, FR; Boeckh, M; Deeg, HJ; Doney, KC; Flowers, ME; Hansen, JA; Heimfeld, S; Kiem, HP; Martin, PJ; McCune, JS; Myerson, D; Nash, RA; O'Donnell, PV; Radich, JP; Sandmaier, BM; Scott, BL; Sorror, ML; Storb, R; Storer, BE; Warren, EH; Witherspoon, RP; Woolfrey, A, 2006) |
| "This prospective study evaluated the outcomes of 75 successive patients receiving a FBC (fludarabine, busulphan, alemtuzumab) reduced-intensity conditioning (RIC) regimen for myelodysplastic syndromes (MDS) using volunteer unrelated donors(VUD)." | 5.12 | Outcomes of alemtuzumab-based reduced intensity conditioning stem cell transplantation using unrelated donors for myelodysplastic syndromes. ( Czepulkowski, B; Devereux, S; Duarte, RF; Ho, AY; Ingram, W; Kenyon, M; Lim, ZY; Mufti, GJ; Pagliuca, A; Pearce, L, 2006) |
| " We report the results of allografting following conditioning with fludarabine, busulphan, and alemtuzumab in 62 patients with myelodysplastic syndromes (MDSs) (matched sibling donors [24] or volunteer unrelated donors [VUDs, 38])." | 5.11 | Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning. ( Devereux, S; Ho, AY; Kenyon, M; Mijovic, A; Mufti, GJ; Pagliuca, A; Parker, JE, 2004) |
| "Sixty-two adults underwent marrow or blood stem cell transplantation from an HLA-matched related donor using high-dose thiotepa, busulfan, and cyclophosphamide (TBC) as the preparative regimen for treatment of advanced myelodysplastic syndrome (MDS) (refractory anemia with excess blasts with or without transformation) or acute myelogenous leukemia (AML) past first remission." | 5.09 | Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia. ( Abi-Said, D; Anderlini, P; Andersson, BS; Andreeff, M; Bibawi, S; Braunschweig, I; Champlin, R; Claxton, D; Donato, M; Estey, EH; Fayad, L; Gajewski, J; Giralt, S; Khouri, I; Mehra, R; Przepiorka, D; Ueno, NT; van Besien, K, 2001) |
| "We have previously demonstrated that hydroxyurea (HU) reduces the rate of vascular complications in patients with essential thrombocythaemia (ET) at high risk of thrombosis." | 5.09 | Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial. ( Barbui, T; Finazzi, G; Rodeghiero, F; Ruggeri, M, 2000) |
| "To investigate the safety and efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for myelodysplastic syndrome (MDS) and secondary acute myelogenous leukemia (MDS-AML) using conditioning regimen with busulfan (Bu) and increased-dose of fludarabine (ID-Flu)." | 3.81 | [Combination of busulfan with increased-dose of fludarabine as conditioning regimen for MDS and MDS-AML patients with allo-HSCT]. ( Cen, X; Dong, Y; Li, Y; Liang, Z; Liu, W; Ou, J; Qiu, Z; Ren, H; Sun, Y; Wang, L; Wang, M; Wang, Q; Wang, W; Xu, W; Yin, Y; Yuan, J, 2015) |
| " We therefore assessed 83 patients (age, 16-70 years): 68 with acute leukemia (including 34 in remission and 34 with refractory disease) and 15 patients with myelodysplastic syndrome, in HCT trials using RIC with busulfan, fludarabine, and antithymocyte globulin." | 3.77 | Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome. ( Hwang, HJ; Jeon, M; Jung, AR; Kang, YA; Kim, DY; Kim, SH; Lee, JH; Lee, KH; Lee, YS; Seol, M; Shin, HJ; Yun, SC, 2011) |
| "Busulfan (Bu)-based preparative regimens have not been extensively investigated in Hodgkin disease (HD)." | 3.73 | Long-term outcome of Hodgkin disease patients following high-dose busulfan, etoposide, cyclophosphamide, and autologous stem cell transplantation. ( Andrèsen, S; Avalos, B; Bolwell, B; Copelan, E; Elder, P; Farag, S; Kalaycio, M; Lin, T; Marcucci, G; Penza, S; Pohlman, B; Sobecks, R; Wadehra, N, 2006) |
| "Postulating favorable antileukemic effect with improved safety, we used intravenous busulfan and fludarabine as conditioning therapy for allogeneic hematopoietic stem cell transplantation (HSCT) for acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS)." | 3.72 | Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. ( Andersson, BS; Champlin, RE; Couriel, D; de Lima, M; Giralt, S; Jones, R; Korbling, M; Madden, T; Pierre, B; Russell, JA; Shahjahan, M; Shpall, EJ; Thall, PF; Wang, X, 2004) |
| "Eighty-three patients with various chronic myeloproliferative disorders [polycythemia vera (PV), essential thrombocytosis (ET), idiopathic myelofibrosis (IMF)] were analyzed for the occurrence of acute myeloid leukemia (AML) and myelodysplasia (MDS) during treatment with hydroxyurea (HU) alone or HU following treatment with busulphan (BU)." | 3.72 | Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan. ( Hasselbalch, HC; Nielsen, I, 2003) |
| " Graft-versus-host disease prophylaxis consisted of cyclosporine and a short course of methotrexate." | 3.71 | A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome. ( Kabisch, H; Kröger, N; Krüger, W; Renges, H; Schetelig, J; Schrum, J; Siegert, W; Stute, N; Zabelina, T; Zander, AR, 2001) |
| " Graft-versus-host disease (GVHD) prophylaxis consisted of T-cell depletion with IgM monoclonal antibody T10B9 plus complement and posttransplant cyclosporine-A." | 3.69 | Unrelated bone marrow donor transplants for children with leukemia or myelodysplasia. ( Baxter-Lowe, LA; Bunin, N; Camitta, B; Casper, J; Garbrecht, F; Hunter, J; Lawton, C; Murray, K; Pietryga, D; Truitt, R, 1995) |
| " We evaluated engraftment of all patients with acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML) and myelodysplastic syndrome (MDS) receiving an unmanipulated marrow allogeneic BMT at the Detroit Medical Center from 1987 to 1992 using a busulfan, cyclophosphamide +/- cytarabine preparative regimen." | 3.69 | Graft failure in children receiving HLA-mismatched marrow transplants with busulfan-containing regimens. ( Abella, E; de Planque, MM; Eisenbrey, AB; Karanes, C; Lum, LG; Ratanatharathorn, V; Ravindranath, Y; Schultz, KR; Sensenbrenner, LL; Uberti, JP, 1994) |
| " We reviewed our experience using busulfan and cyclophosphamide (CY), instead of TBI, as the preparative regimen for allogeneic BMT to study the incidence and relationship to graft-versus-host disease (GVHD) of post-treatment eosinophilia." | 3.69 | Eosinophilia after allogeneic bone marrow transplantation using the busulfan and cyclophosphamide preparative regimen. ( Bolwell, BJ; Kalaycioglu, ME, 1994) |
| "A 77-year-old male, who had been treated with carboquone and busulfan for polycythemia vera (PV), developed myelodysplastic syndrome (MDS) 8 years later." | 3.68 | [Polycythemia vera terminating in myelodysplastic syndrome]. ( Abe, T; Kimura, S; Kobayashi, Y; Kondo, M; Maruo, N; Ozawa, M; Tanaka, R; Uoshima, N; Yoshida, Y, 1990) |
| "Preparative regimens containing busulfan (BU) followed by allogeneic bone marrow transplantation (BMT) were used in 27 consecutive patients with myelodysplastic syndromes (MDS)." | 3.68 | Busulfan-based regimens and allogeneic bone marrow transplantation in patients with myelodysplastic syndromes. ( Cronin, S; Dan, ME; de Planque, MM; Hussein, M; Karanes, C; Lum, LG; Mohamed, A; Ratanatharathorn, V; Schultz, KR; Uberti, J, 1993) |
| "Strategies to reduce recurrence are urgently required." | 3.01 | Augmented Reduced-Intensity Regimen Does Not Improve Postallogeneic Transplant Outcomes in Acute Myeloid Leukemia. ( Andrew, G; Byrne, J; Craddock, C; Crawley, C; Dillon, R; Freeman, SD; Gilleece, M; Hodgkinson, A; Hunter, A; Jackson, A; Khan, N; Loke, J; Malladi, R; Mason, J; McCarthy, N; Nagra, S; Parker, A; Pavlu, J; Peniket, A; Potter, V; Protheroe, R; Salim, R; Siddique, S; Tholouli, E; Vyas, P; Wheatley, K; Wilson, K, 2021) |
| "Busulfan levels were monitored to avoid excess toxicity." | 2.84 | Radiation-free, alternative-donor HCT for Fanconi anemia patients: results from a prospective multi-institutional study. ( Baker, KS; Boulad, F; Davies, SM; Guinan, E; Kernan, NA; Lane, A; Leemhuis, T; Lehmann, L; Margolis, D; Mehta, PA; Myers, K; O'Reilly, RJ; Prockop, SE; Scaradavou, A; Williams, DA, 2017) |
| "Clofarabine has potent antileukemia activity and its inclusion in reduced-intensity conditioning (RIC) allogeneic hematopoietic stem cell transplantation (HSCT) for acute leukemia could potentially improve outcomes." | 2.82 | Phase II Trial of Reduced-Intensity Busulfan/Clofarabine Conditioning with Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Acute Myeloid Leukemia, Myelodysplastic Syndromes, and Acute Lymphoid Leukemia. ( Alyea, E; Ballen, KK; Chen, YB; Cutler, C; Dey, BR; Driscoll, J; El-Jawahri, A; Ho, VT; Hunnewell, C; Li, S; McAfee, SL; Poliquin, C; Saylor, M; Soiffer, RJ; Spitzer, TR, 2016) |
| "Forty-three patients with high-risk hematologic malignancies (median age, 43 years) were enrolled between December 2011 and September 2013." | 2.82 | Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation. ( Appelbaum, FR; Carpenter, PA; Flowers, ME; Furlong, T; Martin, PJ; McCune, JS; Mielcarek, M; O'Donnell, PV; Storb, R; Storer, BE, 2016) |
| " Fifty-eight patients (median age, 67 years; range, 54 to 76) received radioimmunotherapy followed by fludarabine 150 mg/m(2) and busulfan 8 mg/kg combined with either 75 mg (n = 26) or 50 mg (n = 32) alemtuzumab." | 2.80 | Reduced-Intensity Conditioning Combined with (188)Rhenium Radioimmunotherapy before Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia: The Role of In Vivo T Cell Depletion. ( Bornhäuser, M; Ehninger, G; Kotzerke, J; Schetelig, J; Schneider, S; Strumpf, A; Wunderlich, G, 2015) |
| "In AML patients, minimal residual disease (MRD; n = 10) at the time of HCT predicted higher relapse incidence (70% versus 18%) and lower OS (41% versus 79%) at 2 years, when compared with patients without MRD." | 2.79 | Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia. ( Appelbaum, FR; Bar, M; Baumgart, J; Deeg, HJ; Delaney, C; Estey, EH; Fang, M; Gutman, J; Gyurkocza, B; Maziarz, RT; Milano, F; Nemecek, ER; Pagel, JM; Ramakrishnan, A; Sandmaier, BM; Scott, B; Storer, BE; Wood, B, 2014) |
| "Secondary myelodysplastic syndrome and acute myelogenous leukemia (sMDS/sAML) are the most serious secondary events occurring after immunosuppressive therapy in patients with aplastic anemia." | 2.79 | Hematopoietic stem cell transplantation in children and young adults with secondary myelodysplastic syndrome and acute myelogenous leukemia after aplastic anemia. ( Baumann, I; Führer, M; Furlan, I; Göhring, G; Niemeyer, CM; Nöllke, P; Schlegelberger, B; Schwarz, S; Strahm, B; Teigler-Schlegel, A; Walther, JU; Yoshimi, A, 2014) |
| "Comparing patients with acute myeloid leukemia/myelodysplastic syndrome versus those with acute lymphoblastic leukemia/bi-phenotypic leukemia, the 1-year overall and leukemia-free survival rates were 75±10% versus 50±13%, respectively (P=0." | 2.79 | Results from a clofarabine-busulfan-containing, reduced-toxicity conditioning regimen prior to allogeneic stem cell transplantation: the phase 2 prospective CLORIC trial. ( Bilger, K; Blaise, D; Chevallier, P; de La Tour, RP; Delaunay, J; El-Cheikh, J; Furst, S; Guillaume, T; Labopin, M; Lioure, B; Michallet, M; Milpied, N; Mohty, M; Moreau, P; Socié, G; Tabrizi, R; Vigouroux, S, 2014) |
| " Multivariate analysis (MVA) identified comorbidity score (HCT-CI) >2 and advanced disease as adverse factors with no independent impact of regimen." | 2.77 | Allo-SCT for AML and MDS with treosulfan compared with BU-based regimens: reduced toxicity vs reduced intensity. ( Danylesko, I; Nagler, A; Shem-Tov, N; Shimoni, A; Volchek, Y; Yerushalmi, R, 2012) |
| "The optimal pretransplant regimen for acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) in patients ≥ 55 years of age remains to be determined." | 2.76 | Myeloablative reduced-toxicity i.v. busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth decades of life. ( Alatrash, G; Andersson, BS; Champlin, RE; Chiattone, A; de Lima, M; de Padua Silva, L; Giralt, SA; Hamerschlak, N; Hosing, C; Kebriaei, P; Kerbauy, F; Nieto, Y; Pelosini, M; Qazilbash, MH; Rondon, G; Saliba, RM; Wang, X; Xiao, L; Zhang, W, 2011) |
| "The final pharmacokinetic parameter were the clearance (CL/F) = 0." | 2.75 | Population pharmacokinetic study of a test dose oral busulfan in Japanese adult patients undergoing hematopoietic stem cell transplantation. ( Hara, S; Jimi, S; Ogata, K; Sasaki, N; Takamatsu, Y; Tamura, K; Yukawa, E, 2010) |
| " We infused busulfan once daily at 130 mg/m2 for 4 days, performing pharmacokinetic analyses on plasma concentration-time data (n = 60 patients) on days 1, 3, and/or 4." | 2.73 | Pharmacokinetics of once-daily IV busulfan as part of pretransplantation preparative regimens: a comparison with an every 6-hour dosing schedule. ( Andersson, BS; Champlin, RE; Couriel, D; de Lima, M; Jones, RB; Madden, T; Nguyen, J; Pierre, B; Roberson, S; Shpall, EJ; Thapar, N, 2007) |
| "A population pharmacokinetic analysis was performed in 30 patients who received an intravenous busulfan and cyclophosphamide regimen before hematopoietic stem cell transplantation." | 2.72 | Population pharmacokinetics of intravenous busulfan in patients undergoing hematopoietic stem cell transplantation. ( Nakashima, D; Takama, H; Takaue, Y; Tanaka, H; Ueda, R, 2006) |
| " In summary, the combination of treosulfan and fludarabine is a safe and efficient conditioning regimen." | 2.71 | Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation. ( Casper, J; Dölken, G; Freund, M; Hammer, U; Hartung, G; Kiefer, T; Kleine, HD; Knauf, W; Knopp, A; Steiner, B; Wegener, R; Wilhelm, S; Wolff, D, 2004) |
| "The CI of relapse was 25% at 3 years." | 2.70 | Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome after conditioning with busulfan and fractionated total body irradiation is associated with low relapse rate but considerable nonrelapse mortality. ( Anasetti, C; Anderson, JE; Appelbaum, FR; Bryant, E; Chauncey, T; Deeg, HJ; Doney, K; Flowers, ME; Hansen, J; Jurado, M; Martin, PJ; Nash, RA; Petersdorf, E; Radich, J; Sale, G; Sandmaier, BM; Storb, R; Storer, B; Wade, J; Witherspoon, R, 2002) |
| "Cladribine (2-CdA) is a purine analogue that exhibits activity against a variety of hematological malignancies and has a potent immunosuppressive effect." | 2.70 | Therapeutic potential of a reduced-intensity preparative regimen for allogeneic transplantation with cladribine, busulfan, and antithymocyte globulin against advanced/refractory acute leukemia/lymphoma. ( Kami, M; Kanai, S; Kanda, Y; Kato, K; Kawano, Y; Makimoto, A; Matsubara, H; Mineishi, S; Nakai, K; Ogasawara, T; Ohnishi, T; Saito, T; Shoji, N; Takaue, Y; Tanosaki, R; Tobinai, K; Wakasugi, H, 2002) |
| "One of the MPDs, chronic myeloid leukemia (CML), has the distinct cytogenetic abnormality of the Philadelphia chromosome." | 2.42 | Treatment paradigms in the management of myeloproliferative disorders. ( Fruchtman, SM, 2004) |
| " The prediction of transplantation-related mortality (TRM) using the Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) score and an arbitrary upper age limit of 55 years for administering myeloablative conditioning (MAC) are common strategies to ensure a safe procedure." | 1.91 | Myeloablative Dose of Busulfan and Fludarabine Combined with In Vivo T Cell Depletion Is Safe and Effective Conditioning for Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients. ( Alshehri, H; Anteh, S; Avenoso, D; Bourlon, C; Bouziana, S; Dazzi, F; de Farias, M; Dragoi, OD; Gameil, A; Hannah, G; Kenyon, M; Krishnamurthy, P; Kulasekararaj, A; Leung, YT; Mehra, V; Pagliuca, A; Potter, V; Serpenti, F; Shah, MN; Slonim, LB; Wood, H, 2023) |
| " PT was graded using Common Terminology Criteria for Adverse Events version 5." | 1.72 | Comparison of Pulmonary Toxicity after Total Body Irradiation- and Busulfan-Based Myeloablative Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Patients. ( Chen, YH; Duncan, CN; Lehmann, LE; Liu, KX; Marcus, KJ; Margossian, S; Moore, N; Poux, N; Shin, KY; Whangbo, JS, 2022) |
| "Outcomes were compared in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome who received either myeloablative, fractionated busulfan (f-Bu) dosed to achieve an area under the curve of 20,000 μmol per minute (f-Bu20K) over 2 weeks (n = 84) or a standard, nonfractionated, lower busulfan dose regimen of 16,000 μmol per minute (Bu16K) over 4 days (n = 78)." | 1.62 | Fractionated busulfan myeloablative conditioning improves survival in older patients with acute myeloid leukemia and myelodysplastic syndrome. ( Alousi, AM; Andersson, BS; Bashir, Q; Champlin, RE; Chen, J; Ciurea, SO; Hosing, C; Kebriaei, P; Marin, D; Mehta, RS; Olson, AL; Oran, B; Popat, UR; Rezvani, K; Saliba, RM; Shpall, EJ; Valdez, BC, 2021) |
| "Busulfan was considered the cause in the first reported case because the transgene was not present in the AML/MDS." | 1.62 | Leukemia after gene therapy for sickle cell disease: insertional mutagenesis, busulfan, both, or neither. ( DeBaun, MR; Jones, RJ, 2021) |
| " The RIC and MAC regimens were dosed at the average daily area under the concentration-vs-time curve (AUC) of 4000 µMol min and 5000-6000 µMol min, or total course AUC of 16,000 µMol min and 20,000-24,000 µMol min, respectively; PK-guided dosing removes overlap in systemic Bu exposure." | 1.51 | Reduced intensity vs. myeloablative conditioning with fludarabine and PK-guided busulfan in allogeneic stem cell transplantation for patients with AML/MDS. ( Alatrash, G; Andersson, BS; Champlin, RE; Chen, J; Crain, AK; Di Stasi, A; Jones, RB; Kidwell, KM; Popat, U; Shpall, EJ; Thall, PF; Zope, M, 2019) |
| " There is still an important variation in Bu pharmacokinetic between patients that is associated with an increased risk of toxicity and graft failure." | 1.48 | Pharmacokinetics-adapted Busulfan-based myeloablative conditioning before unrelated umbilical cord blood transplantation for myeloid malignancies in children. ( Ansari, M; Benadiba, J; Bittencourt, H; Cellot, S; Duval, M; Krajinovic, M; Teira, P; Vachon, MF, 2018) |
| " Moreover, it appears to be safe with a low NRM rate among high-risk patients." | 1.43 | The efficacy and safety of a new reduced-toxicity conditioning with 4 days of once-daily 100 mg/m(2) intravenous busulfan associated with fludarabine and antithymocyte globulins prior to allogeneic stem cell transplantation in patients with high-risk myel ( Blaise, D; Calmels, B; Castagna, L; Chabannon, C; Crocchiolo, R; Devillier, R; El-Cheikh, J; Faucher, C; Furst, S; Granata, A; Harbi, S; Lemarie, C; Vey, N; Wanquet, A; Weiller, PJ, 2016) |
| " Pharmacokinetic dosing of busulfan (Bu) is frequently done for myeloablative conditioning, but evidence for its use is limited in RIC transplants." | 1.43 | Fludarabine-Busulfan Reduced-Intensity Conditioning in Comparison with Fludarabine-Melphalan Is Associated with Increased Relapse Risk In Spite of Pharmacokinetic Dosing. ( Al-Kali, A; Alkhateeb, HB; Damlaj, M; Gangat, N; Gastineau, DA; Hashmi, S; Hefazi, M; Hogan, WJ; Litzow, MR; Partain, DK; Patnaik, MM; Wolf, RC, 2016) |
| "busulfan (Bu) has been shown to be highly effective as a pretransplant conditioning regimen in acute myeloid leukemia (AML), chronic myeloid leukemia (CML), and myelodysplastic syndrome (MDS)." | 1.43 | Long-Term Outcomes after Treatment with Clofarabine ± Fludarabine with Once-Daily Intravenous Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and Myelodysplastic Syndrome. ( Alatrash, G; Alousi, AM; Andersson, BS; Champlin, RE; Chen, J; de Lima, M; Fox, PS; Garber, HR; Hosing, C; Janbey, S; Jones, RB; Kebriaei, P; Ning, J; Popat, U; Rondon, G; Shpall, EJ; Thall, PF; Valdez, BC; Worth, LL, 2016) |
| "Busulfan is a commonly used chemotherapeutic agent in myeloablative conditioning regimens for allogeneic hematopoietic cell transplantation (allo-HCT)." | 1.42 | Subacute hepatic necrosis mimicking veno-occlusive disease in a patient with HFE H63D homozygosity after allogeneic hematopoietic cell transplantation with busulfan conditioning. ( Boyer, MW; Chen, S; Chen, X; Hildebrandt, GC; McDonald, GB; Osborn, JD, 2015) |
| " busulfan dosing (total dose 3." | 1.39 | Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia. ( Alyea, EP; Antin, JH; Armand, P; Attar, EC; Ballen, KK; Chen, YB; Coughlin, E; Cutler, C; Dey, BR; Ho, VT; Kennedy, KF; Koreth, J; McAfee, SL; Soiffer, RJ; Spitzer, TR, 2013) |
| "The ACTH stimulation test demonstrated primary adrenal insufficiency, and the other etiologies of primary adrenal insufficiency were excluded." | 1.37 | Primary adrenal insufficiency in a child after busulfan and cyclophosphamide-based conditioning for hematopoietic stem cell transplantation. ( Berberoglu, M; Ertem, M; Hacihamdioglu, B; Ileri, T; Ince, EU; Ocal, G; Savas-Erdeve, S; Siklar, Z; Uysal, Z, 2011) |
| " The goal of this retrospective analysis was to evaluate any age-related pharmacokinetic and pharmacodynamic differences in pediatric patients who received BU as a conditioning agent." | 1.35 | Evaluating pharmacokinetics and pharmacodynamics of intravenous busulfan in pediatric patients receiving bone marrow transplantation. ( Ikeda, A; Kim, AH; Moore, TB; Tse, JC, 2009) |
| "Busulfan is an alkylating agent currently used in the myeloablative conditioning regimen before stem cell transplantation." | 1.31 | The pharmacodynamic effect of busulfan in the P39 myeloid cell line in vitro. ( Hassan, M; Hassan, Z; Hellström-Lindberg, E, 2001) |
| " Although busulfan is used frequently in children as part of a myeloablative regimen prior to bone marrow transplantation, pharmacokinetic data on intravenous busulfan in children are scarce." | 1.31 | Pharmacokinetics of intravenous busulfan in children prior to stem cell transplantation. ( Ball, L; Bredius, R; Cremers, S; den Hartigh, J; Schoemaker, R; Twiss, I; Vermeij, P; Vossen, J, 2002) |
| "Diagnosis at time of presentation was refractory anemia with excess of blasts (RAEB) in two patients, RAEB in transformation (RAEB-t) in three, and juvenile chronic myelogenous leukemia (JCML, the pediatric counterpart of adult chronic myelomonocytic leukemia) in the remaining three children." | 1.29 | Busulfan, cyclophosphamide and melphalan as conditioning regimen for bone marrow transplantation in children with myelodysplastic syndromes. ( Bonetti, F; Cazzola, M; Locatelli, F; Maserati, E; Paolucci, P; Pedrazzoli, P; Pession, A; Prete, A; Prete, L; Zecca, M, 1994) |
| "Thirty-eight patients had chronic myelogenous leukemia (17 patients chronic phase, 13 patients accelerated phase, eight patients blast phase), 19 patients had acute leukemia (second complete remission or relapse) and eight patients had myelodysplasia." | 1.29 | Unrelated allogeneic bone marrow transplantation using high-dose busulfan and cyclophosphamide (BU-CY) for the preparative regimen. ( Avalos, B; Bolwell, B; Copelan, E; Crilley, P; Gajewski, J; Klein, J; Sahebi, F; Territo, M, 1996) |
| "Clonal chromosome aberrations observed in patients who have relapsed after autologous bone marrow transplantation (ABMT) are usually related to the cytogenetic abnormalities observed at diagnosis." | 1.29 | Detection of occasional and clonal chromosome aberrations in patients with acute non-lymphocytic leukemia after autologous bone marrow transplantation. ( Gherlinzoni, F; Manfroi, S; Mangianti, S; Martinelli, G; Miggiano, MC; Pelliconi, S; Testoni, N; Tura, S; Visani, G; Zaccaria, A, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (1.70) | 18.7374 |
| 1990's | 34 (19.32) | 18.2507 |
| 2000's | 53 (30.11) | 29.6817 |
| 2010's | 65 (36.93) | 24.3611 |
| 2020's | 21 (11.93) | 2.80 |
| Authors | Studies |
|---|---|
| Kurosawa, S | 2 |
| Shimomura, Y | 2 |
| Itonaga, H | 2 |
| Najima, Y | 2 |
| Kobayashi, T | 2 |
| Ozawa, Y | 3 |
| Kanda, Y | 7 |
| Kako, S | 3 |
| Kawakita, T | 2 |
| Matsuoka, KI | 2 |
| Maruyama, Y | 2 |
| Ota, S | 2 |
| Nakazawa, H | 2 |
| Imada, K | 2 |
| Kanda, J | 2 |
| Fukuda, T | 3 |
| Atsuta, Y | 3 |
| Aoki, J | 2 |
| Shimoni, A | 6 |
| Robin, M | 2 |
| Iacobelli, S | 2 |
| Beelen, D | 1 |
| Mufti, GJ | 3 |
| Ciceri, F | 3 |
| Bethge, W | 3 |
| Volin, L | 5 |
| Blaise, D | 4 |
| Ganser, A | 1 |
| Luft, T | 1 |
| Chevallier, P | 3 |
| Schwerdtfeger, R | 2 |
| Koster, L | 1 |
| de Witte, T | 2 |
| Kröger, N | 7 |
| Nagler, A | 6 |
| Yakoub-Agha, I | 1 |
| O'Hagan Henderson, S | 1 |
| Frietsch, JJ | 1 |
| Hilgendorf, I | 3 |
| Hochhaus, A | 1 |
| Köhne, CH | 1 |
| Casper, J | 7 |
| Kimura, T | 1 |
| Ishiyama, K | 2 |
| Beelen, DW | 3 |
| Stelljes, M | 3 |
| Reményi, P | 1 |
| Wagner-Drouet, EM | 1 |
| Dreger, P | 2 |
| Stölzel, F | 1 |
| Junghanß, C | 1 |
| Labussiere-Wallet, H | 1 |
| Schaefer-Eckart, K | 1 |
| Grigoleit, GU | 1 |
| Scheid, C | 2 |
| Patriarca, F | 1 |
| Rambaldi, A | 1 |
| Niederwieser, D | 2 |
| Russo, D | 1 |
| Socié, G | 3 |
| Holler, E | 1 |
| Glass, B | 1 |
| Wulf, G | 1 |
| Basara, N | 1 |
| Bieniaszewska, M | 1 |
| Stuhler, G | 2 |
| Verbeek, M | 1 |
| La Rocca, U | 1 |
| Finke, J | 5 |
| Benedetti, F | 1 |
| Pichlmeier, U | 3 |
| Klein, A | 1 |
| Baumgart, J | 3 |
| Markiewicz, M | 2 |
| Liu, KX | 1 |
| Poux, N | 1 |
| Shin, KY | 1 |
| Moore, N | 1 |
| Chen, YH | 2 |
| Margossian, S | 1 |
| Whangbo, JS | 1 |
| Duncan, CN | 1 |
| Lehmann, LE | 1 |
| Marcus, KJ | 1 |
| Truscott, L | 3 |
| Pariury, H | 3 |
| Hanmod, S | 3 |
| Davini, M | 3 |
| de la Maza, M | 3 |
| Sapp, LN | 3 |
| Staples, K | 3 |
| Proytcheva, M | 3 |
| Katsanis, E | 3 |
| Xuan, L | 1 |
| Dai, M | 1 |
| Jiang, E | 1 |
| Wang, Y | 1 |
| Huang, F | 1 |
| Fan, Z | 1 |
| Xu, N | 1 |
| Nie, D | 1 |
| Liang, X | 1 |
| Chen, H | 1 |
| Ye, J | 1 |
| Shi, P | 1 |
| Liu, H | 3 |
| Jin, H | 1 |
| Lin, R | 1 |
| Yan, C | 1 |
| Zhang, Y | 1 |
| Sun, J | 1 |
| Han, M | 1 |
| Liu, Q | 1 |
| Cassanello, G | 1 |
| Serpenti, F | 2 |
| Bagnoli, F | 1 |
| Saporiti, G | 1 |
| Goldaniga, M | 1 |
| Cavallaro, F | 1 |
| Barbullushi, K | 1 |
| Bellani, V | 1 |
| Galassi, G | 1 |
| Onida, F | 2 |
| Avenoso, D | 1 |
| Mehra, V | 1 |
| Slonim, LB | 1 |
| de Farias, M | 1 |
| Alshehri, H | 1 |
| Bouziana, S | 1 |
| Krishnamurthy, P | 1 |
| Kulasekararaj, A | 1 |
| Dazzi, F | 1 |
| Wood, H | 1 |
| Kenyon, M | 3 |
| Leung, YT | 1 |
| Anteh, S | 1 |
| Shah, MN | 1 |
| Hannah, G | 1 |
| Gameil, A | 1 |
| Bourlon, C | 1 |
| Dragoi, OD | 1 |
| Pagliuca, A | 3 |
| Potter, V | 2 |
| Yu, ZP | 2 |
| Ding, JH | 2 |
| Sun, AN | 2 |
| Chen, BA | 2 |
| Ge, Z | 2 |
| Wu, DP | 2 |
| Cao, YG | 1 |
| He, Y | 2 |
| Zhang, SD | 1 |
| Liu, ZX | 1 |
| Zhai, WH | 2 |
| Ma, QL | 2 |
| Pang, AM | 2 |
| Wei, JL | 2 |
| Yang, DL | 2 |
| Huang, Y | 1 |
| Feng, SZ | 2 |
| Jiang, EL | 2 |
| Han, MZ | 2 |
| Jentzsch, M | 1 |
| Döhring, C | 1 |
| Linke, R | 1 |
| Hille, A | 1 |
| Grimm, J | 1 |
| Pönisch, W | 1 |
| Vucinic, V | 1 |
| Franke, GN | 2 |
| Behre, G | 1 |
| Schwind, S | 1 |
| Patel, SS | 1 |
| Rybicki, L | 2 |
| Pohlman, B | 4 |
| Bolwell, B | 5 |
| Gerds, AT | 2 |
| Hamilton, BK | 2 |
| Hanna, R | 2 |
| Kalaycio, M | 5 |
| Majhail, NS | 3 |
| Sobecks, R | 2 |
| Oshrine, B | 1 |
| Adams, L | 1 |
| Nguyen, ATH | 1 |
| Amankwah, E | 1 |
| Shyr, D | 1 |
| Hale, G | 1 |
| Petrovic, A | 1 |
| Wedge, E | 1 |
| Sengeløv, H | 1 |
| Hansen, JW | 1 |
| Andersen, NS | 1 |
| Schjødt, I | 1 |
| Petersen, SL | 1 |
| Kornblit, B | 1 |
| Grønbæk, K | 1 |
| Friis, LS | 1 |
| Uchida, N | 2 |
| Matsumoto, K | 1 |
| Sakura, T | 1 |
| Hidaka, M | 1 |
| Miyamoto, T | 1 |
| Eto, T | 2 |
| Maeda, Y | 1 |
| Murayama, T | 1 |
| Fujishima, N | 1 |
| Yoshimoto, G | 1 |
| Morita, K | 1 |
| Kishimoto, J | 1 |
| Teshima, T | 1 |
| Taniguchi, S | 3 |
| Yamashita, T | 1 |
| Mori, SI | 1 |
| Akashi, K | 1 |
| Harada, M | 1 |
| D'Angelo, CR | 1 |
| Hall, A | 1 |
| Woo, KM | 1 |
| Kim, K | 1 |
| Longo, W | 1 |
| Hematti, P | 1 |
| Callander, N | 1 |
| Kenkre, VP | 1 |
| Mattison, R | 1 |
| Juckett, M | 1 |
| Yao, W | 1 |
| Chu, X | 1 |
| Fang, X | 1 |
| Zhu, X | 1 |
| Tang, B | 1 |
| Wan, X | 1 |
| Geng, L | 1 |
| Tong, J | 1 |
| Song, K | 1 |
| Zhang, X | 2 |
| Qiang, P | 1 |
| Sun, G | 1 |
| Sun, Z | 1 |
| Craddock, C | 1 |
| Jackson, A | 1 |
| Loke, J | 1 |
| Siddique, S | 1 |
| Hodgkinson, A | 1 |
| Mason, J | 1 |
| Andrew, G | 1 |
| Nagra, S | 1 |
| Malladi, R | 1 |
| Peniket, A | 1 |
| Gilleece, M | 1 |
| Salim, R | 1 |
| Tholouli, E | 1 |
| Crawley, C | 1 |
| Wheatley, K | 1 |
| Protheroe, R | 1 |
| Vyas, P | 1 |
| Hunter, A | 1 |
| Parker, A | 1 |
| Wilson, K | 1 |
| Pavlu, J | 1 |
| Byrne, J | 1 |
| Dillon, R | 1 |
| Khan, N | 1 |
| McCarthy, N | 1 |
| Freeman, SD | 1 |
| Oran, B | 3 |
| Saliba, RM | 3 |
| Mehta, RS | 1 |
| Alousi, AM | 2 |
| Marin, D | 1 |
| Valdez, BC | 2 |
| Chen, J | 4 |
| Bashir, Q | 1 |
| Ciurea, SO | 1 |
| Olson, AL | 1 |
| Hosing, C | 3 |
| Kebriaei, P | 4 |
| Rezvani, K | 1 |
| Shpall, EJ | 6 |
| Champlin, RE | 10 |
| Andersson, BS | 10 |
| Popat, UR | 1 |
| Jones, RJ | 1 |
| DeBaun, MR | 1 |
| Ahn, KW | 1 |
| Fretham, C | 1 |
| Beitinjaneh, A | 1 |
| Bashey, A | 2 |
| Pawarode, A | 1 |
| Wirk, B | 1 |
| Scott, BL | 5 |
| Savani, BN | 1 |
| Bredeson, C | 1 |
| Weisdorf, D | 1 |
| Marks, DI | 1 |
| Rizzieri, D | 1 |
| Copelan, E | 6 |
| Hildebrandt, GC | 2 |
| Hale, GA | 2 |
| Murthy, HS | 1 |
| Lazarus, HM | 1 |
| Cerny, J | 1 |
| Liesveld, JL | 1 |
| Yared, JA | 1 |
| Yves-Cahn, J | 1 |
| Szer, J | 1 |
| Verdonck, LF | 1 |
| Aljurf, M | 1 |
| van der Poel, M | 1 |
| Litzow, M | 1 |
| Grunwald, MR | 1 |
| Diaz, MA | 1 |
| Sabloff, M | 1 |
| Kharfan-Dabaja, MA | 1 |
| Farhadfar, N | 1 |
| Reshef, R | 1 |
| Olsson, RF | 1 |
| Gale, RP | 1 |
| Nakamura, R | 1 |
| Seo, S | 1 |
| Chhabra, S | 1 |
| Hashmi, S | 2 |
| Farhan, S | 1 |
| Ganguly, S | 1 |
| Nathan, S | 1 |
| Nishihori, T | 1 |
| Jain, T | 1 |
| Agrawal, V | 1 |
| Bacher, U | 1 |
| Popat, U | 4 |
| Saber, W | 1 |
| Pasquini, MC | 1 |
| Logan, BR | 1 |
| Wu, J | 2 |
| Devine, SM | 1 |
| Porter, DL | 1 |
| Maziarz, RT | 3 |
| Warlick, ED | 1 |
| Fernandez, HF | 1 |
| Alyea, EP | 4 |
| Hamadani, M | 1 |
| Giralt, S | 6 |
| Geller, NL | 1 |
| Leifer, E | 1 |
| Le-Rademacher, J | 1 |
| Mendizabal, AM | 1 |
| Horowitz, MM | 1 |
| Deeg, HJ | 13 |
| Horwitz, ME | 1 |
| Platzbecker, U | 1 |
| Uddin, R | 1 |
| Hübel, K | 1 |
| Weber, T | 1 |
| Afanasyev, B | 1 |
| Heim, D | 1 |
| Deliliers, GL | 1 |
| Pini, M | 1 |
| Guidi, S | 1 |
| Günther, A | 1 |
| Poiré, X | 1 |
| Kobbe, G | 2 |
| van Os, M | 1 |
| Brand, R | 1 |
| Vago, L | 1 |
| Bernardi, M | 1 |
| Yerushalmi, R | 3 |
| Peccatori, J | 1 |
| Greco, R | 1 |
| Shem-Tov, N | 3 |
| Lo Russo, A | 1 |
| Danylesko, I | 3 |
| Apel, A | 1 |
| Bonini, C | 1 |
| Lupo Stanghellini, MT | 1 |
| Spitzer, B | 1 |
| Jakubowski, AA | 2 |
| Papadopoulos, EB | 2 |
| Fuller, K | 1 |
| Hilden, PD | 1 |
| Young, JW | 3 |
| Barker, JN | 1 |
| Koehne, G | 1 |
| Perales, MA | 3 |
| Hsu, KC | 2 |
| van den Brink, MR | 1 |
| Kernan, NA | 3 |
| Prockop, SE | 2 |
| Scaradavou, A | 2 |
| Castro-Malaspina, H | 2 |
| O'Reilly, RJ | 3 |
| Boulad, F | 3 |
| Kawamura, K | 1 |
| Mizuta, S | 1 |
| Yano, S | 1 |
| Iwato, K | 1 |
| Kanamori, H | 1 |
| Kahata, K | 1 |
| Kondo, T | 1 |
| Sawa, M | 1 |
| Ichinohe, T | 1 |
| Barrett, A | 1 |
| Catherwood, M | 1 |
| Thornton, P | 1 |
| Murphy, P | 1 |
| Quinn, J | 1 |
| Gooptu, M | 1 |
| Kim, HT | 2 |
| Ho, VT | 3 |
| Koreth, J | 2 |
| Armand, P | 2 |
| Ritz, J | 2 |
| Nikiforow, S | 1 |
| Glotzbecker, BE | 1 |
| Nageshwar, P | 1 |
| Soiffer, RJ | 4 |
| Antin, JH | 3 |
| Cutler, CS | 1 |
| Benadiba, J | 1 |
| Ansari, M | 1 |
| Krajinovic, M | 1 |
| Vachon, MF | 1 |
| Duval, M | 1 |
| Teira, P | 1 |
| Cellot, S | 1 |
| Bittencourt, H | 1 |
| Gayoso, J | 1 |
| Balsalobre, P | 1 |
| Kwon, M | 1 |
| Herrera, P | 1 |
| Bermúdez, A | 2 |
| Sampol, A | 2 |
| Jiménez, S | 1 |
| López-Corral, L | 1 |
| Serrano, D | 2 |
| Piñana, JL | 2 |
| Pascual, MJ | 1 |
| Heras, I | 2 |
| Bento, L | 1 |
| Varela, R | 1 |
| Humala, K | 1 |
| Zabalza, A | 1 |
| Laiglesia, A | 1 |
| Bastos-Oreiro, M | 1 |
| Pérez-Corral, A | 1 |
| Martínez-Laperche, C | 1 |
| Buño, I | 1 |
| Díez-Martín, JL | 1 |
| Khalil, MMI | 1 |
| Messner, HA | 1 |
| Lipton, JH | 2 |
| Kim, DD | 1 |
| Viswabandya, A | 1 |
| Thyagu, S | 1 |
| Deotare, U | 1 |
| Michelis, FV | 1 |
| Park, SS | 1 |
| Jeon, YW | 2 |
| Min, GJ | 1 |
| Park, S | 1 |
| Yahng, SA | 2 |
| Yoon, JH | 2 |
| Shin, SH | 2 |
| Lee, SE | 2 |
| Cho, BS | 2 |
| Eom, KS | 3 |
| Lee, S | 4 |
| Kim, HJ | 4 |
| Min, CK | 4 |
| Cho, SG | 2 |
| Lee, JW | 4 |
| Kim, YJ | 4 |
| Alatrash, G | 4 |
| Kidwell, KM | 1 |
| Thall, PF | 5 |
| Di Stasi, A | 1 |
| Zope, M | 1 |
| Crain, AK | 1 |
| Jones, RB | 4 |
| Lee, CC | 1 |
| Chang, HH | 1 |
| Lu, MY | 1 |
| Yang, YL | 1 |
| Chou, SW | 1 |
| Lin, DT | 1 |
| Jou, ST | 1 |
| Yao, M | 1 |
| Li, CC | 1 |
| Yeh, SP | 1 |
| Chen, MH | 1 |
| Gau, JP | 1 |
| Li, SS | 1 |
| Wang, PN | 1 |
| Liu, YC | 1 |
| Wang, TF | 1 |
| Tan, TD | 1 |
| Lee, MY | 1 |
| Yu, MS | 1 |
| Wang, CC | 1 |
| Lin, SC | 1 |
| Chen, YC | 1 |
| Su, YC | 1 |
| Su, KY | 1 |
| Lin, KH | 1 |
| Ohta, T | 1 |
| Sugio, Y | 1 |
| Imanaga, H | 1 |
| Oku, S | 1 |
| Ohno, Y | 1 |
| Zhao, XL | 1 |
| Mårtensson, T | 1 |
| Priftakis, P | 1 |
| Casswall, T | 1 |
| Ringdén, O | 4 |
| Mattsson, J | 1 |
| Remberger, M | 3 |
| Hassan, M | 3 |
| Gustafsson, B | 1 |
| Chen, YB | 2 |
| Coughlin, E | 1 |
| Kennedy, KF | 1 |
| Attar, EC | 1 |
| Ballen, KK | 2 |
| Cutler, C | 3 |
| Dey, BR | 2 |
| McAfee, SL | 2 |
| Spitzer, TR | 2 |
| Rezvani, AR | 1 |
| McCune, JS | 3 |
| Storer, BE | 5 |
| Batchelder, A | 1 |
| Kida, A | 1 |
| McDonald, GB | 4 |
| Gao, L | 2 |
| Gong, Y | 1 |
| Zhang, C | 1 |
| Chen, XH | 1 |
| Yoshimi, A | 1 |
| Strahm, B | 1 |
| Baumann, I | 1 |
| Furlan, I | 1 |
| Schwarz, S | 1 |
| Teigler-Schlegel, A | 1 |
| Walther, JU | 1 |
| Schlegelberger, B | 1 |
| Göhring, G | 1 |
| Nöllke, P | 1 |
| Führer, M | 1 |
| Niemeyer, CM | 1 |
| Gyurkocza, B | 1 |
| Gutman, J | 1 |
| Nemecek, ER | 2 |
| Bar, M | 1 |
| Milano, F | 1 |
| Ramakrishnan, A | 1 |
| Scott, B | 2 |
| Fang, M | 1 |
| Wood, B | 1 |
| Pagel, JM | 2 |
| Delaney, C | 1 |
| Sandmaier, BM | 4 |
| Estey, EH | 2 |
| Appelbaum, FR | 13 |
| Kim, JH | 2 |
| Stein, A | 1 |
| Tsai, N | 1 |
| Schultheiss, TE | 1 |
| Palmer, J | 1 |
| Liu, A | 1 |
| Rosenthal, J | 1 |
| Forman, SJ | 2 |
| Wong, JY | 1 |
| Labopin, M | 1 |
| Tabrizi, R | 1 |
| Furst, S | 3 |
| Lioure, B | 2 |
| Guillaume, T | 1 |
| Delaunay, J | 1 |
| de La Tour, RP | 1 |
| Vigouroux, S | 1 |
| El-Cheikh, J | 2 |
| Michallet, M | 3 |
| Bilger, K | 1 |
| Milpied, N | 3 |
| Moreau, P | 1 |
| Mohty, M | 2 |
| Choi, YS | 1 |
| Kim, DY | 5 |
| Lee, JH | 10 |
| Lee, KH | 5 |
| Min, WS | 3 |
| Schneider, S | 1 |
| Strumpf, A | 1 |
| Schetelig, J | 2 |
| Wunderlich, G | 1 |
| Ehninger, G | 4 |
| Kotzerke, J | 1 |
| Bornhäuser, M | 5 |
| Yuan, J | 1 |
| Ren, H | 1 |
| Qiu, Z | 1 |
| Li, Y | 1 |
| Wang, M | 1 |
| Liu, W | 1 |
| Xu, W | 1 |
| Sun, Y | 1 |
| Wang, L | 1 |
| Liang, Z | 1 |
| Dong, Y | 1 |
| Ou, J | 1 |
| Wang, W | 1 |
| Yin, Y | 1 |
| Cen, X | 1 |
| Wang, Q | 1 |
| Lee, HC | 1 |
| Rondon, G | 4 |
| Charafeddine, Y | 1 |
| Medeiros, LJ | 1 |
| Ciurea, S | 1 |
| Shpall, E | 1 |
| Champlin, R | 2 |
| El-Jawahri, A | 1 |
| Li, S | 1 |
| Driscoll, J | 1 |
| Hunnewell, C | 1 |
| Poliquin, C | 1 |
| Saylor, M | 1 |
| Alyea, E | 1 |
| Nakamae, H | 1 |
| Koh, H | 1 |
| Katayama, T | 1 |
| Nishimoto, M | 1 |
| Hayashi, Y | 1 |
| Nakashima, Y | 1 |
| Nakane, T | 1 |
| Nakamae, M | 1 |
| Hirose, A | 1 |
| Hino, M | 2 |
| Chen, S | 1 |
| Osborn, JD | 1 |
| Chen, X | 1 |
| Boyer, MW | 1 |
| Ravinet, A | 1 |
| Cabrespine, A | 1 |
| Yakoub Agha, I | 1 |
| Nguyen, S | 1 |
| Menard, AL | 1 |
| Maillard, N | 1 |
| Suarez, F | 1 |
| Huynh, A | 1 |
| Marchand, T | 1 |
| Deteix, C | 1 |
| Cassuto, JP | 1 |
| Maury, S | 1 |
| Reman, O | 1 |
| Peffault de Latour, R | 1 |
| Bay, JO | 1 |
| Mielcarek, M | 1 |
| Furlong, T | 1 |
| O'Donnell, PV | 2 |
| Storb, R | 7 |
| Carpenter, PA | 1 |
| Flowers, ME | 5 |
| Martin, PJ | 5 |
| Shaffer, BC | 1 |
| Le Luduec, JB | 1 |
| Forlenza, C | 1 |
| Wanquet, A | 1 |
| Crocchiolo, R | 2 |
| Granata, A | 1 |
| Faucher, C | 2 |
| Devillier, R | 2 |
| Harbi, S | 1 |
| Lemarie, C | 1 |
| Calmels, B | 1 |
| Vey, N | 2 |
| Weiller, PJ | 1 |
| Chabannon, C | 2 |
| Castagna, L | 2 |
| De La Serna, J | 1 |
| Sanz, J | 1 |
| Cabrero, M | 1 |
| Vallejo, C | 1 |
| Gómez, V | 1 |
| Moraleda, JM | 3 |
| Perez, SG | 1 |
| Caballero, MD | 2 |
| Conde, E | 1 |
| Lahuerta, JJ | 1 |
| Sanz, G | 1 |
| Choi, EJ | 1 |
| Park, HS | 1 |
| Seol, M | 3 |
| Lee, YS | 3 |
| Kang, YA | 3 |
| Jeon, M | 3 |
| Damlaj, M | 1 |
| Alkhateeb, HB | 1 |
| Hefazi, M | 1 |
| Partain, DK | 1 |
| Gastineau, DA | 1 |
| Al-Kali, A | 1 |
| Wolf, RC | 1 |
| Gangat, N | 1 |
| Litzow, MR | 1 |
| Hogan, WJ | 1 |
| Patnaik, MM | 1 |
| Fox, PS | 1 |
| Ning, J | 1 |
| Garber, HR | 1 |
| Janbey, S | 1 |
| Worth, LL | 1 |
| de Lima, M | 6 |
| Mustafa Ali, M | 1 |
| Abounader, DM | 1 |
| Rybicki, LA | 1 |
| Yurch, MA | 1 |
| Starn, J | 1 |
| Ferraro, C | 1 |
| Winslow, V | 1 |
| Dean, R | 2 |
| Hill, BT | 1 |
| Andresen, S | 3 |
| Bolwell, BJ | 3 |
| Sobecks, RM | 2 |
| Maher, OM | 1 |
| Silva, JG | 1 |
| Liu, D | 1 |
| Cooper, LJ | 1 |
| Tarek, N | 1 |
| Worth, L | 2 |
| Lee, DA | 1 |
| Petropoulos, D | 2 |
| Franklin, AR | 1 |
| Zweidler-Mckay, P | 1 |
| Wells, RJ | 1 |
| Tewari, P | 1 |
| Mehta, PA | 1 |
| Davies, SM | 2 |
| Leemhuis, T | 1 |
| Myers, K | 1 |
| Williams, DA | 1 |
| Lehmann, L | 1 |
| Guinan, E | 1 |
| Margolis, D | 1 |
| Baker, KS | 2 |
| Lane, A | 1 |
| Kim, AH | 1 |
| Tse, JC | 1 |
| Ikeda, A | 1 |
| Moore, TB | 1 |
| Kerbauy, FR | 2 |
| Tirapelli, B | 1 |
| Akabane, H | 1 |
| Oliveira, JS | 1 |
| Takamatsu, Y | 1 |
| Sasaki, N | 1 |
| Ogata, K | 1 |
| Yukawa, E | 1 |
| Jimi, S | 1 |
| Hara, S | 1 |
| Tamura, K | 1 |
| Uberti, JP | 2 |
| Agovi, MA | 1 |
| Tarima, S | 1 |
| Haagenson, M | 1 |
| Gandham, S | 1 |
| Anasetti, C | 8 |
| Chan, KW | 1 |
| Kollman, C | 1 |
| McCarthy, PL | 1 |
| Ratanatharathorn, V | 5 |
| Weisdorf, DJ | 1 |
| Rizzo, JD | 1 |
| Atallah, E | 1 |
| Abrams, J | 1 |
| Ayash, L | 1 |
| Bentley, G | 1 |
| Abidi, M | 1 |
| Uberti, J | 3 |
| Wolff, D | 2 |
| Gromke, T | 1 |
| Trenschel, R | 2 |
| Elmaagacli, AH | 1 |
| Junghanss, C | 1 |
| Freund, M | 4 |
| Guthrie, KA | 1 |
| Sorror, ML | 2 |
| Wood, BL | 1 |
| Doney, KC | 3 |
| Hilger, RA | 1 |
| Kovacsovics, TJ | 1 |
| Woolfrey, AE | 1 |
| Bedalov, A | 2 |
| Sanders, JE | 3 |
| Sickle, EJ | 1 |
| Witherspoon, R | 2 |
| Rodrigues, M | 1 |
| de Souza Santos, FP | 1 |
| Sobrinho, JN | 1 |
| Kutner, JM | 1 |
| Torres, MA | 1 |
| Ribeiro, AA | 1 |
| Hamerschlak, N | 2 |
| Pelosini, M | 1 |
| Wang, X | 3 |
| Xiao, L | 1 |
| Kerbauy, F | 1 |
| Chiattone, A | 1 |
| Qazilbash, MH | 1 |
| Giralt, SA | 1 |
| de Padua Silva, L | 1 |
| Zhang, W | 1 |
| Nieto, Y | 1 |
| Sweiss, K | 1 |
| Patel, P | 1 |
| Rondelli, D | 2 |
| Wong, AM | 1 |
| Allen, JC | 1 |
| Goh, YT | 1 |
| Linn, YC | 1 |
| Loh, SM | 1 |
| Diong, CP | 1 |
| Chowbay, B | 1 |
| Hwang, WY | 1 |
| Choi, SJ | 1 |
| Yun, SC | 2 |
| Joo, YD | 2 |
| Lee, WS | 2 |
| Kang, MJ | 1 |
| Kim, H | 2 |
| Park, JH | 2 |
| Bae, SH | 2 |
| Ryoo, HM | 2 |
| Kim, MK | 2 |
| Hyun, MS | 2 |
| Ruutu, T | 3 |
| Schnitzler, M | 1 |
| Holowiecki, J | 2 |
| Giebel, S | 2 |
| Uharek, L | 1 |
| Blau, IW | 1 |
| Kienast, J | 1 |
| Larsson, K | 1 |
| Zander, AR | 3 |
| Gramatzki, M | 1 |
| Repp, R | 1 |
| Einsele, H | 1 |
| Mylius, HA | 1 |
| Hwang, HJ | 1 |
| Jung, AR | 1 |
| Kim, SH | 1 |
| Shin, HJ | 1 |
| Garming-Legert, K | 1 |
| Dahllöf, G | 1 |
| Yurch, M | 1 |
| Duong, H | 1 |
| Saure, C | 1 |
| Schroeder, T | 1 |
| Zohren, F | 1 |
| Groten, A | 1 |
| Bruns, I | 1 |
| Czibere, A | 1 |
| Galonska, L | 1 |
| Kondakci, M | 1 |
| Weigelt, C | 1 |
| Fenk, R | 1 |
| Germing, U | 1 |
| Haas, R | 1 |
| Al-Seraihy, A | 1 |
| Ayas, M | 1 |
| Al-Nounou, R | 1 |
| El-Solh, H | 1 |
| Al-Ahmari, A | 1 |
| Al-Jefri, A | 1 |
| Belgaumi, A | 1 |
| Savas-Erdeve, S | 1 |
| Berberoglu, M | 1 |
| Siklar, Z | 1 |
| Hacihamdioglu, B | 1 |
| Ocal, G | 1 |
| Ertem, M | 1 |
| Ileri, T | 1 |
| Ince, EU | 1 |
| Uysal, Z | 1 |
| El Cheikh, J | 1 |
| Prebet, T | 1 |
| Etienne, A | 1 |
| Esterni, B | 1 |
| Volchek, Y | 1 |
| Lee, GW | 1 |
| Kim, SD | 1 |
| Min, YJ | 1 |
| Storer, B | 5 |
| Slattery, JT | 2 |
| Hansen, JA | 3 |
| Kiem, HP | 2 |
| Petersdorf, E | 2 |
| Radich, JP | 2 |
| Shulman, HM | 2 |
| Warren, EH | 2 |
| Witherspoon, RP | 4 |
| Bryant, EM | 2 |
| Chauncey, TR | 1 |
| Getzendaner, L | 1 |
| Martino, R | 3 |
| Pérez-Simón, JA | 3 |
| Simón, JA | 1 |
| Canals, C | 1 |
| Solano, C | 1 |
| Urbano-Ispízua, A | 1 |
| Bargay, J | 1 |
| Léon, A | 1 |
| Sarrá, J | 1 |
| Sanz, GF | 1 |
| Brunet, S | 1 |
| San Miguel, J | 1 |
| Sierra, J | 3 |
| Wathen, JK | 1 |
| Bekele, BN | 1 |
| Baker, LH | 1 |
| Benjamin, RS | 1 |
| Hansen, J | 2 |
| Nichols, WG | 1 |
| Radich, J | 2 |
| Woolfrey, A | 2 |
| Jenke, A | 2 |
| Schleyer, E | 1 |
| Thiede, C | 1 |
| Biersack, H | 1 |
| Sayer, HG | 1 |
| Wandt, H | 2 |
| Schäfer-Eckardt, K | 1 |
| Beyer, J | 1 |
| Kiehl, M | 1 |
| Knauf, W | 2 |
| Kiefer, T | 1 |
| Steiner, B | 1 |
| Hammer, U | 1 |
| Wegener, R | 1 |
| Kleine, HD | 1 |
| Wilhelm, S | 1 |
| Knopp, A | 1 |
| Hartung, G | 1 |
| Dölken, G | 1 |
| Nielsen, I | 1 |
| Hasselbalch, HC | 1 |
| Benesch, M | 1 |
| Schubert, M | 1 |
| Asano, Y | 1 |
| Ogawa, N | 1 |
| Sakata-Yanagimoto, M | 1 |
| Nakagawa, M | 1 |
| Kawazu, M | 1 |
| Goyama, S | 1 |
| Kandabashi, K | 1 |
| Izutsu, K | 1 |
| Imai, Y | 1 |
| Hangaishi, A | 1 |
| Kurokawa, M | 1 |
| Tsujino, S | 1 |
| Ogawa, S | 1 |
| Aoki, K | 1 |
| Chiba, S | 1 |
| Motokura, T | 1 |
| Hirai, H | 1 |
| Hamaki, T | 1 |
| Kami, M | 3 |
| Kim, SW | 2 |
| Onishi, Y | 1 |
| Kishi, Y | 1 |
| Murashige, N | 1 |
| Hori, A | 2 |
| Kojima, R | 1 |
| Sakiyama, M | 1 |
| Imataki, O | 1 |
| Heike, Y | 1 |
| Tanosaki, R | 3 |
| Masuo, S | 1 |
| Miyakoshi, S | 1 |
| Tobinai, K | 2 |
| Takaue, Y | 4 |
| Ho, AY | 2 |
| Parker, JE | 1 |
| Mijovic, A | 1 |
| Devereux, S | 2 |
| Couriel, D | 3 |
| Madden, T | 2 |
| Jones, R | 1 |
| Shahjahan, M | 1 |
| Pierre, B | 3 |
| Korbling, M | 2 |
| Russell, JA | 2 |
| Blau, I | 1 |
| Schafer-Eckart, K | 1 |
| Aschan, J | 1 |
| Zander, A | 2 |
| Doelken, G | 1 |
| Fruchtman, SM | 1 |
| Chauncey, T | 3 |
| Petersdorf, S | 1 |
| Slattery, J | 1 |
| Appelbaum, F | 1 |
| Spyridonidis, A | 1 |
| Küttler, T | 1 |
| Wäsch, R | 1 |
| Samek, E | 1 |
| Waterhouse, M | 1 |
| Behringer, D | 1 |
| Bertz, H | 2 |
| Kim, DW | 2 |
| Lee, DG | 1 |
| Choi, SM | 1 |
| Kim, CC | 2 |
| Sakamaki, H | 1 |
| Sao, H | 1 |
| Okamoto, S | 1 |
| Kodera, Y | 1 |
| Kasai, M | 1 |
| Hiraoka, A | 1 |
| Takahashi, S | 1 |
| Miyawaki, S | 1 |
| Kawase, T | 1 |
| Morishima, Y | 1 |
| Kato, S | 1 |
| Takama, H | 1 |
| Tanaka, H | 1 |
| Nakashima, D | 1 |
| Ueda, R | 1 |
| Zabelina, T | 2 |
| Schieder, H | 1 |
| Panse, J | 1 |
| Ayuk, F | 1 |
| Wolschke, C | 1 |
| Renges, H | 2 |
| Dahlke, J | 1 |
| Atanackovic, D | 1 |
| Shi, JM | 1 |
| Huang, H | 1 |
| Cai, Z | 1 |
| Luo, Y | 1 |
| Ye, XJ | 1 |
| Zhang, J | 1 |
| Li, L | 1 |
| He, JS | 1 |
| Xie, WZ | 1 |
| Zheng, WY | 1 |
| Meng, XJ | 1 |
| Lin, MF | 1 |
| Boeckh, M | 1 |
| Myerson, D | 1 |
| Heimfeld, S | 1 |
| Nash, RA | 3 |
| Lim, ZY | 1 |
| Ingram, W | 1 |
| Pearce, L | 1 |
| Czepulkowski, B | 1 |
| Duarte, RF | 1 |
| Ho, V | 1 |
| DeAngelo, DJ | 1 |
| Stone, R | 1 |
| Ogawa, H | 1 |
| Ikegame, K | 1 |
| Yoshihara, S | 1 |
| Kawakami, M | 1 |
| Fujioka, T | 1 |
| Masuda, T | 1 |
| Taniguchi, Y | 1 |
| Hasei, H | 1 |
| Kaida, K | 1 |
| Inoue, T | 1 |
| Kim, EH | 1 |
| Kawase, I | 1 |
| Wadehra, N | 1 |
| Farag, S | 1 |
| Elder, P | 1 |
| Penza, S | 1 |
| Avalos, B | 3 |
| Marcucci, G | 1 |
| Lin, T | 1 |
| Thapar, N | 1 |
| Nguyen, J | 1 |
| Roberson, S | 2 |
| Small, TN | 1 |
| Prockop, S | 1 |
| Wilton, A | 1 |
| Heller, G | 1 |
| Chiu, M | 1 |
| Hsu, K | 1 |
| Jakubowski, A | 1 |
| Chang, C | 1 |
| Clurman, BE | 1 |
| Kim, SY | 1 |
| Saito, AM | 1 |
| Mori, S | 1 |
| Suzuki, R | 1 |
| Mineishi, S | 2 |
| Takami, A | 1 |
| Takemoto, Y | 1 |
| Hara, M | 1 |
| Yamaguchi, M | 2 |
| Yoshida, T | 1 |
| Ohashi, Y | 1 |
| Hardan, I | 1 |
| Rand, A | 1 |
| Valcárcel, D | 2 |
| Caballero, D | 2 |
| Martin, J | 1 |
| Ferra, C | 1 |
| Nieto, JB | 1 |
| Bernal, MT | 1 |
| Vazquez, L | 1 |
| Ribera, JM | 1 |
| Besalduch, J | 1 |
| Carrera, D | 1 |
| Brunet, MS | 1 |
| Chunduri, S | 1 |
| Dobogai, LC | 1 |
| Peace, D | 1 |
| Saunthararajah, Y | 1 |
| Quigley, J | 1 |
| Mahmud, N | 1 |
| Hurter, E | 1 |
| Beri, R | 1 |
| Rebollo, N | 1 |
| de la Cámara, R | 1 |
| de Oteiza, JP | 1 |
| Calvo, MV | 1 |
| San Miguel, JF | 1 |
| Novitzky, N | 1 |
| Thomas, V | 1 |
| du Toit, C | 1 |
| Mcdonald, A | 1 |
| Nakao, S | 1 |
| Ueda, M | 1 |
| Takamatsu, H | 1 |
| Tamaru, Y | 1 |
| Shiobara, S | 1 |
| Masauji, N | 1 |
| Matsue, K | 1 |
| Matsuda, T | 1 |
| Camitta, B | 1 |
| Truitt, R | 1 |
| Baxter-Lowe, LA | 1 |
| Bunin, N | 1 |
| Lawton, C | 1 |
| Murray, K | 1 |
| Hunter, J | 1 |
| Pietryga, D | 1 |
| Garbrecht, F | 1 |
| Kalaycioglu, M | 1 |
| Klein, J | 2 |
| Goormastic, M | 1 |
| Rubie, H | 1 |
| Attal, M | 2 |
| Demur, C | 1 |
| Brousset, P | 1 |
| Duchayne, E | 1 |
| Rigal-Huguet, F | 1 |
| Dastugue, N | 1 |
| Robert, A | 1 |
| Schultz, KR | 3 |
| Abella, E | 1 |
| Eisenbrey, AB | 1 |
| Karanes, C | 3 |
| Lum, LG | 3 |
| de Planque, MM | 3 |
| Ravindranath, Y | 1 |
| Sensenbrenner, LL | 1 |
| Kalaycioglu, ME | 1 |
| Przepiorka, D | 3 |
| Ippoliti, C | 1 |
| van Beisen, K | 1 |
| Mehra, R | 2 |
| Deisseroth, AB | 1 |
| Andersson, B | 1 |
| Luna, M | 1 |
| Cork, A | 1 |
| Lee, M | 1 |
| Nikoskelainen, J | 1 |
| Vindeløv, L | 1 |
| Parkkali, T | 1 |
| Lenhoff, S | 1 |
| Sallerfors, B | 1 |
| Ljungman, P | 1 |
| Locatelli, F | 1 |
| Pession, A | 1 |
| Bonetti, F | 1 |
| Maserati, E | 1 |
| Prete, L | 1 |
| Pedrazzoli, P | 1 |
| Zecca, M | 1 |
| Prete, A | 1 |
| Paolucci, P | 1 |
| Cazzola, M | 1 |
| von Bueltzingsloewen, A | 1 |
| Belanger, R | 1 |
| Perreault, C | 1 |
| Bonny, Y | 1 |
| Roy, DC | 1 |
| Lalonde, Y | 1 |
| Boileau, J | 1 |
| Kassis, J | 1 |
| Lavallee, R | 1 |
| Lacombe, M | 1 |
| Cronin, S | 2 |
| Dan, ME | 2 |
| Mohamed, A | 2 |
| Hussein, M | 1 |
| O'Donnell, MR | 1 |
| Long, GD | 1 |
| Parker, PM | 1 |
| Niland, J | 1 |
| Nademanee, A | 1 |
| Amylon, M | 1 |
| Chao, N | 1 |
| Negrin, RS | 1 |
| Schmidt, GM | 1 |
| Slovak, ML | 1 |
| Anderson, JE | 2 |
| Schoch, G | 2 |
| Gooley, T | 1 |
| Bensinger, WI | 1 |
| Bryant, E | 2 |
| Buckner, CD | 2 |
| Clift, RA | 1 |
| Raymakers, R | 1 |
| Stellink, F | 1 |
| Geurts van Kessel, A | 1 |
| Sutton, L | 1 |
| Chastang, C | 1 |
| Ribaud, P | 1 |
| Jouet, JP | 2 |
| Kuentz, M | 1 |
| Reiffers, J | 1 |
| Tigaud, JM | 1 |
| Rio, B | 1 |
| Dauriac, C | 1 |
| Legros, M | 1 |
| Dreyfus, F | 2 |
| Troussard, X | 1 |
| Witz, F | 1 |
| Oriol, P | 1 |
| Cahn, JY | 2 |
| Gluckman, E | 1 |
| Ifrah, N | 1 |
| Pico, JL | 1 |
| Vilmer, E | 1 |
| Leblond, V | 1 |
| deMagalhaes-Silverman, M | 1 |
| Bloom, EJ | 1 |
| Donnenberg, A | 1 |
| Lister, J | 1 |
| Pincus, S | 1 |
| Rybka, WB | 1 |
| Ball, ED | 1 |
| Klein, JL | 1 |
| Avalos, BR | 2 |
| Belt, P | 1 |
| Taylor, CA | 1 |
| Ezzone, SA | 2 |
| Scholl, MD | 2 |
| Fisher, J | 1 |
| Young, D | 1 |
| Copelan, EA | 2 |
| Sahebi, F | 1 |
| Crilley, P | 1 |
| Territo, M | 1 |
| Gajewski, J | 3 |
| Testoni, N | 1 |
| Martinelli, G | 1 |
| Zaccaria, A | 1 |
| Miggiano, MC | 1 |
| Pelliconi, S | 1 |
| Visani, G | 1 |
| Manfroi, S | 1 |
| Gherlinzoni, F | 1 |
| Mangianti, S | 1 |
| Tura, S | 1 |
| Nagatoshi, Y | 1 |
| Okamura, J | 1 |
| Ikuno, Y | 1 |
| Akamatsu, M | 1 |
| Tasaka, H | 1 |
| Al-Fiar, FZ | 1 |
| Colwill, R | 1 |
| Fyles, G | 1 |
| Spaner, D | 1 |
| Messner, H | 1 |
| Potthoff, K | 1 |
| Mertelsmann, R | 1 |
| Tefferi, A | 1 |
| Leahey, AM | 1 |
| Friedman, DL | 1 |
| Bunin, NJ | 1 |
| Wattel, E | 1 |
| Solary, E | 1 |
| Leleu, X | 1 |
| Brion, A | 1 |
| Hoang-Ngoc, L | 1 |
| Maloisel, F | 1 |
| Guerci, A | 1 |
| Rochant, H | 1 |
| Gratecos, N | 1 |
| Casassus, P | 1 |
| Janvier, M | 1 |
| Brice, P | 1 |
| Lepelley, P | 1 |
| Fenaux, P | 1 |
| Randi, ML | 2 |
| Fabris, F | 2 |
| Girolami, A | 2 |
| Tran, H | 1 |
| Culbert, S | 1 |
| Mullen, C | 1 |
| Roberts, W | 1 |
| Chan, K | 1 |
| Penza, SL | 1 |
| Elder, PJ | 1 |
| Bechtel, TP | 1 |
| Belt, PS | 1 |
| Donato, M | 2 |
| Gian, V | 1 |
| Wingard, J | 1 |
| Tarantolo, S | 1 |
| Fernandez, H | 1 |
| Hu, WW | 1 |
| Blume, K | 1 |
| Kashyap, A | 1 |
| Finazzi, G | 1 |
| Ruggeri, M | 1 |
| Rodeghiero, F | 1 |
| Barbui, T | 1 |
| Bieri, S | 1 |
| Helg, C | 1 |
| Chapuis, B | 1 |
| Miralbell, R | 1 |
| Bibawi, S | 1 |
| Abi-Said, D | 1 |
| Fayad, L | 1 |
| Anderlini, P | 1 |
| Ueno, NT | 1 |
| Khouri, I | 1 |
| Claxton, D | 1 |
| Braunschweig, I | 1 |
| van Besien, K | 1 |
| Andreeff, M | 1 |
| Hassan, Z | 1 |
| Hellström-Lindberg, E | 1 |
| Schuler, US | 1 |
| Renner, UD | 1 |
| Kroschinsky, F | 1 |
| Johne, C | 1 |
| Naumann, R | 1 |
| Krüger, W | 1 |
| Stute, N | 1 |
| Schrum, J | 1 |
| Kabisch, H | 1 |
| Siegert, W | 1 |
| Jurado, M | 1 |
| Doney, K | 1 |
| Sale, G | 1 |
| Wade, J | 1 |
| Saito, T | 1 |
| Kato, K | 1 |
| Shoji, N | 1 |
| Kanai, S | 1 |
| Ohnishi, T | 1 |
| Kawano, Y | 1 |
| Nakai, K | 1 |
| Ogasawara, T | 1 |
| Matsubara, H | 1 |
| Makimoto, A | 1 |
| Wakasugi, H | 1 |
| Cremers, S | 1 |
| Schoemaker, R | 1 |
| Bredius, R | 1 |
| den Hartigh, J | 1 |
| Ball, L | 1 |
| Twiss, I | 1 |
| Vermeij, P | 1 |
| Vossen, J | 1 |
| Nevill, TJ | 1 |
| Shepherd, JD | 1 |
| Reece, DE | 1 |
| Barnett, MJ | 1 |
| Nantel, SH | 1 |
| Klingemann, HG | 1 |
| Phillips, GL | 1 |
| Leisz, MC | 1 |
| Tiberghien, P | 1 |
| Flesch, M | 1 |
| Paintaud, G | 1 |
| Emminger, W | 1 |
| Emminger-Schmidmeier, W | 1 |
| Peters, C | 1 |
| Gadner, H | 1 |
| Usuka, Y | 1 |
| Saito, Y | 1 |
| Barrall, J | 1 |
| Fisher, LD | 1 |
| Ramberg, RE | 1 |
| Shulman, H | 1 |
| Bearman, SI | 1 |
| Beatty, P | 1 |
| Kimura, S | 1 |
| Uoshima, N | 1 |
| Tanaka, R | 1 |
| Kobayashi, Y | 1 |
| Ozawa, M | 1 |
| Maruo, N | 1 |
| Kondo, M | 1 |
| Abe, T | 1 |
| Yoshida, Y | 1 |
| Bowcock, SJ | 1 |
| Galton, DA | 1 |
| Goldman, JM | 1 |
| Knottenbelt, E | 1 |
| Hallett, J | 1 |
| Jacobs, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Decitabine Followed by Bone Marrow Transplant and High-Dose Cyclophosphamide for the Treatment of Relapsed and Refractory Acute Myeloid Neoplasms[NCT01707004] | Phase 2 | 20 participants (Actual) | Interventional | 2013-05-16 | Completed | ||
| Reduced Intensity Conditioning With Fludarabine and Busulfan Versus Fludarabine and Melphalan Before Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Randomised, Single-Center, Phase III Study[NCT05674539] | Phase 3 | 200 participants (Anticipated) | Interventional | 2022-12-28 | Recruiting | ||
| A Phase 1/2 Study Evaluating Gene Therapy by Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo With the LentiGlobin BB305 Lentiviral Vector in Subjects With Severe Sickle Cell Disease[NCT02140554] | Phase 1/Phase 2 | 50 participants (Anticipated) | Interventional | 2014-08-31 | Active, not recruiting | ||
| Allogeneic Hematopoietic Cell Transplant for Hematological Cancers and Myelodysplastic Syndromes in HIV-Infected Individuals (BMT CTN #0903)[NCT01410344] | Phase 2 | 20 participants (Actual) | Interventional | 2011-09-30 | Completed | ||
| A Randomized, Multi-Center, Phase III Study of Allogeneic Stem Cell Transplantation Comparing Regimen Intensity in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia (BMT CTN #0901)[NCT01339910] | Phase 3 | 272 participants (Actual) | Interventional | 2011-06-30 | Terminated (stopped due to Accrual terminated as recommended by the data and safety monitoring board.) | ||
| A Phase II Open-label, Multicenter, Non Randomized Study Evaluating the Efficacy and the Safety of Clofarabine in Combination With IV Busulfan and Thymoglobulin (CBT) as a Reduced Intensity Conditioning Regimen Prior to Allogeneic Stem Cell Transplantatio[NCT00863148] | Phase 2 | 30 participants (Actual) | Interventional | 2009-10-31 | Completed | ||
| A Phase II Study to Evaluate the Efficacy of Posttransplant Cyclophosphamide for Prevention of Chronic Graft-versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation[NCT01427881] | Phase 2 | 43 participants (Actual) | Interventional | 2011-09-30 | Completed | ||
| Prospective and Multicentre Evaluation of 3 Different Doses of IV Busulfan Associated With Fludarabine and Thymoglobuline in the Conditioning of Allogeneic Stem Cell Transplantation (SCT) From a Matched Related or Unrelated Donor in Patients With Poor Pro[NCT01985061] | Phase 2 | 177 participants (Anticipated) | Interventional | 2013-12-31 | Recruiting | ||
| A Multicenter Phase II Trial of Hematopoietic Stem Cell Transplantation for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine[NCT00987480] | Phase 2 | 45 participants (Actual) | Interventional | 2009-09-25 | Completed | ||
| Intensive Conditioning Regimen With Thiotepa Combined With Busulfan, Fludarabine and Cytarabine for Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of Myeloid Malignancies With Extramedullary Involvement[NCT06111612] | 50 participants (Anticipated) | Observational | 2024-01-01 | Not yet recruiting | |||
| A Phase I/II Feasibility Study of Gene Transfer for Artemis-Deficient Severe Combined Immunodeficiency (ART-SCID) Using a Self-Inactivating Lentiviral Vector (AProArt) to Transduce Autologous CD34 Hematopoietic Cells[NCT03538899] | Phase 1/Phase 2 | 25 participants (Anticipated) | Interventional | 2018-05-31 | Recruiting | ||
| Unrelated Donor Hematopoietic Stem Cell Transplantation After Nonmyeloablative Conditioning For Patients With Hematological Malignancies[NCT00627666] | Phase 2 | 52 participants (Anticipated) | Interventional | 2003-01-31 | Completed | ||
| Clinical Phase II Trial to Evaluate the Safety and Efficacy of Treosulfan Based Conditioning Prior to Allogeneic Haematopoietic Stem Cell Transplantation in Patients With Myelodysplastic Syndrome (MDS)[NCT01062490] | Phase 2 | 45 participants (Actual) | Interventional | 2004-11-30 | Completed | ||
| NON-T-CELL DEPLETED HLA-HAPLOIDENTICAL FAMILIAL DONOR HEMATOPOIETIC CELL TRANSPLANTATION AFTER REDUCED INTENSITY CONDITIONING[NCT00521430] | 30 participants (Anticipated) | Interventional | 2004-04-30 | Completed | |||
| HLA-HAPLOIDENTICAL FAMILIAL DONOR HEMATOPOIETIC CELL TRANSPLANTATION AFTER REDUCED INTENSITY CONDITIONING OF BUSULFAN, FLUDARABINE, AND ANTI-THYMOCYTE GLOBULIN FOR ADULT PATIENTS WITH HEMATOLOGIC MALIGNANCIES AND MYELODYSPLASTIC SYNDROME - A PHASE 2 STUDY[NCT00732316] | Phase 2 | 54 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
| Phase I Trial of Haploidentical Natural Killer (NK) Cells in Combination With Pemetrexed in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)[NCT03366064] | Phase 1 | 5 participants (Actual) | Interventional | 2017-11-09 | Completed | ||
| A Prospective Study Evaluating the Efficacy of the Allogeneic Hematopoietic Cell Transplantation With Antithymocyte Globulin (ATG)-Based Conditioning of Adult Acute Lymphoblastic Leukemia in First / Second Complete Hematologic Remission[NCT02428517] | 20 participants (Actual) | Observational | 2015-04-30 | Terminated (stopped due to The PI resigned the institute, and the rest investigators at the institute decided to terminate the study.) | |||
| Allogeneic HCT From Donor-sources of Matched-sibling, Matched-unrelated, or Haploidentical-family Donors Using Uniform Conditioning Regimen of Busulfan, Fludarabine, and Antithymocyte Globulin for AML in Remission - an Observational Study[NCT03337568] | 110 participants (Anticipated) | Observational | 2017-04-01 | Recruiting | |||
| HLA-Haploidentical Hematopoietic Cell Transplantation and Subsequent Donor Natural Killer Cell Infusion in Refractory Acute Leukemia - A Phase 1-2a STUDY[NCT01795378] | Phase 1/Phase 2 | 56 participants (Actual) | Interventional | 2013-02-28 | Completed | ||
| Randomized Comparison of Once-daily Intravenous Busulfan Plus Cyclophosphamide Versus Fludarabine as a Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation in Leukemia and Myelodysplastic Syndrome[NCT00774280] | Phase 3 | 130 participants (Actual) | Interventional | 2002-05-31 | Completed | ||
| Single Arm Phase II Study of Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation for Acute Lymphoblastic Leukemia (ALL) in Older Patients Using Fludarabine and Total Body Irradiation (FluTBI) Regimen[NCT01991457] | Phase 2 | 19 participants (Actual) | Interventional | 2013-08-27 | Completed | ||
| The Study of New RIC Regimen of BuFlu in Older or Intolerable Patients With Hematologic Malignant Diseases[NCT01828619] | 60 participants (Anticipated) | Observational | 2013-02-28 | Enrolling by invitation | |||
| Single Arm, Open Label, Phase I Study for Dose and Schedule Finding of Decitabine in Patients With Higher-risk MDS and MDS/AML Receiving Allogeneic Stem Cell Transplantation[NCT01277484] | Phase 1 | 19 participants (Actual) | Interventional | 2011-01-31 | Active, not recruiting | ||
| Phase II Trial of Fludarabine Combined With Intravenous Treosulfan and Allogeneic Hematopoietic Stem-cell Transplantation in Patients With Chemo-refractory or Previously Untreated Acute Myeloid Leukemia and Myelodysplastic Syndrome.[NCT00491634] | Phase 2 | 24 participants (Anticipated) | Interventional | 2007-06-30 | Completed | ||
| PRO#1278: A Phase III Study of Fludarabine and Busulfan Versus Fludarabine, Busulfan and Low Dose Total Body Irradiation in Patients Receiving an Allogeneic Hematopoietic Stem Cell Transplant[NCT01366612] | Phase 3 | 53 participants (Actual) | Interventional | 2010-06-16 | Terminated (stopped due to Lack of Accrual) | ||
| Intrabone Infusion of Cord Blood Hemopoietic Stem Cells in Adult Patients With High Risk Haematological Malignancies.[NCT00886522] | Phase 2 | 23 participants (Actual) | Interventional | 2009-04-30 | Completed | ||
| A Phase II Study of Pevonedistat (MLN4924, TAK924) and Azacitidine as Maintenance Therapy After Allogeneic Stem Cell Transplantation for Non-Remission Acute Myelogenous Leukemia[NCT03709576] | Phase 2 | 3 participants (Actual) | Interventional | 2018-07-18 | Terminated (stopped due to Funding pulled) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Will be summarized with a proportion and a 95% confidence interval. (NCT01707004)
Timeframe: Up to 1 year
| Intervention | percentage (Number) |
|---|---|
| Decitabine + Bone Marrow Transplant | 40.7 |
Determined by the standard bone marrow transplant (BMT) Clinical Trials Network criteria (BMTCTN). Will be analyzed using KM method, a Graft versus Host Disease (GVHD) grade III-IV will be obtained from the KM estimates along with 95% confidence intervals. (NCT01707004)
Timeframe: Day 100
| Intervention | percentage of participants (Number) |
|---|---|
| Decitabine + Bone Marrow Transplant | 27.8 |
(NCT01707004)
Timeframe: Up to 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Decitabine + Bone Marrow Transplant | 14 |
Defined as less than 5% donor chimerism in the cluster of differentiation (CD)3 and CD33 selected cell populations at any time after transplantation. Will be analyzed using KM method. (NCT01707004)
Timeframe: Day 30
| Intervention | Participants (Count of Participants) |
|---|---|
| Decitabine + Bone Marrow Transplant | 0 |
Will be analyzed using Kaplan-Meier (KM) method, and OS will be obtained from the KM estimates along with 95% confidence intervals. (NCT01707004)
Timeframe: Day 100
| Intervention | percentage of participants (Number) |
|---|---|
| Decitabine + Bone Marrow Transplant | 64.7 |
Platelet recovery is defined as the first day of a platelet count greater than 20,000/mm^3 with no platelet transfusions. Will be summarized with mean and standard deviation or median and interquartile range, and the change will be tested using a one-sample paired t-test at a two-tailed significance level of 0.05. (NCT01707004)
Timeframe: Up to day 30
| Intervention | percentage with plt engraftment, day 30 (Number) |
|---|---|
| Decitabine + Bone Marrow Transplant | 58 |
(NCT01707004)
Timeframe: Up to 1 year
| Intervention | days (Median) |
|---|---|
| Decitabine + Bone Marrow Transplant | 141 |
Defined as achieving an absolute neutrophil count (ANC) greater than or equal to 500/ul for three consecutive measurements on different days. Will be summarized with mean and standard deviation or median and interquartile range, and the change will be tested using a one-sample paired t-test at a two-tailed significance level of 0.05. (NCT01707004)
Timeframe: Up to 1 year
| Intervention | days (Mean) |
|---|---|
| Decitabine + Bone Marrow Transplant | 16 |
Chronic GVHD is classified per 2005 NIH Consensus Criteria (Filipovich et al. 2005) into categories of severity: none, mild, moderate, and severe. Occurrence of chronic GVHD is defined as the occurrence of mild, moderate, or severe chronic GVHD per this classification. (NCT01410344)
Timeframe: 1 Year Post-transplant
| Intervention | percentage of participants (Number) |
|---|---|
| Allogeneic Transplant | 17.6 |
Relapse/Progression is defined as relapse or progression of the primary malignancy. (NCT01410344)
Timeframe: 1 Year Post-transplant
| Intervention | percentage of participants (Number) |
|---|---|
| Allogeneic Transplant | 29.4 |
Recovery of hematologic function is described by the time to neutrophil and platelet recovery. Time to neutrophil recovery will be the first of three consecutive days of > 500 neutrophils/μL following the expected nadir. Time to platelet engraftment will be described by the date when platelet count is > 20,000/μL for the first of three consecutive labs with no platelet transfusions 7 days prior. (NCT01410344)
Timeframe: Days 28 and 100 Post-transplant
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Day 28 Neutrophil Recovery | Day 100 Platelet Recovery | |
| Allogeneic Transplant | 100.0 | 94.1 |
"Acute GVHD is graded according to the scoring system proposed by Przepiorka et al.1995:~Skin stage:~0: No rash~Rash <25% of body surface area~Rash on 25-50% of body surface area~Rash on > 50% of body surface area~Generalized erythroderma with bullous formation~Liver stage (based on bilirubin level)*:~0: <2 mg/dL 1.2-3 mg/dL 2.3.01-6 mg/dL 3.6.01-15.0 mg/dL 4.>15 mg/dL~GI stage*:~0: No diarrhea or diarrhea <500 mL/day~Diarrhea 500-999 mL/day or persistent nausea with histologic evidence of GVHD~Diarrhea 1000-1499 mL/day~Diarrhea >1500 mL/day~Severe abdominal pain with or without ileus * If multiple etiologies are listed for liver or GI, the organ system is downstaged by 1.~GVHD grade:~0: All organ stages 0 or GVHD not listed as an etiology I: Skin stage 1-2 and liver and GI stage 0 II: Skin stage 3 or liver or GI stage 1 III: Liver stage 2-3 or GI stage 2-4 IV: Skin or liver stage 4" (NCT01410344)
Timeframe: Day 100 Post-transplant
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Grade II-IV Acute GVHD | Grade III-IV Acute GVHD | |
| Allogeneic Transplant | 41.2 | 11.8 |
The events for non-relapse mortality are death due to any cause other than relapse of the underlying malignancy. (NCT01410344)
Timeframe: Day 100, 1 Year, and 2 Years Post-transplant
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| Day 100 | 1 Year | 2 Years | |
| Allogeneic Transplant | 0.0 | 11.8 | 18.3 |
Overall survival is defined as the time from transplant to death from any cause. (NCT01410344)
Timeframe: Six months, 1 Year, and 2 Years Post-transplant
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| 6 Months | 1 Year | 2 Years | |
| Allogeneic Transplant | 82.4 | 58.8 | 50.2 |
Donor T-cell and myeloid chimerism will be described separately by conditioning regimen intensity (myeloablative or reduced intensity) according to proportions with mixed chimerism (5-95% donor cells out of all), full chimerism (>95% donor cells), or graft rejection (<5% donor cells). (NCT01410344)
Timeframe: Week 4, Day 100, and 6 months Post-transplant
| Intervention | Participants (Count of Participants) | |||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 472365409 | Week 472365410 | Day 10072365410 | Day 10072365409 | 6 Months72365409 | 6 Months72365410 | |||||||||||||||||||||||||
| Graft Rejection | No Assay Reported | Full Chimerism | Mixed Chimerism | Dead at Assessment | ||||||||||||||||||||||||||
| Reduced Intensity Allogeneic Transplant | 4 | |||||||||||||||||||||||||||||
| Myeloablative Allogeneic Transplant | 1 | |||||||||||||||||||||||||||||
| Myeloablative Allogeneic Transplant | 3 | |||||||||||||||||||||||||||||
| Myeloablative Allogeneic Transplant | 4 | |||||||||||||||||||||||||||||
| Reduced Intensity Allogeneic Transplant | 5 | |||||||||||||||||||||||||||||
| Myeloablative Allogeneic Transplant | 2 | |||||||||||||||||||||||||||||
| Reduced Intensity Allogeneic Transplant | 2 | |||||||||||||||||||||||||||||
| Myeloablative Allogeneic Transplant | 0 | |||||||||||||||||||||||||||||
| Reduced Intensity Allogeneic Transplant | 0 | |||||||||||||||||||||||||||||
Primary graft failure is defined by lack of neutrophil engraftment. (NCT01339910)
Timeframe: 28 days post-transplant
| Intervention | Participants (Count of Participants) |
|---|---|
| Myeloablative Conditioning Regimen (MAC) | 1 |
| Reduced Intensity Conditioning (RIC) | 3 |
Secondary graft failure is defined by initial neutrophil engraftment followed by subsequent decline in neutrophil counts to less than 500x10^6/liter that is unresponsive to growth factor therapy. (NCT01339910)
Timeframe: 18 months post-transplant
| Intervention | Participants (Count of Participants) |
|---|---|
| Myeloablative Conditioning Regimen (MAC) | 1 |
| Reduced Intensity Conditioning (RIC) | 4 |
Chronic GVHD is classified per 2005 NIH Consensus Criteria (Filipovich et al. 2005) into categories of severity: none, mild, moderate, and severe. Occurrence of chronic GVHD is defined as the occurrence of mild, moderate, or severe chronic GVHD per this classification. (NCT01339910)
Timeframe: 18 months post-transplant
| Intervention | percentage (Number) |
|---|---|
| Myeloablative Conditioning Regimen (MAC) | 64.0 |
| Reduced Intensity Conditioning (RIC) | 47.6 |
Disease Relapse is defined as relapse of the primary disease. (NCT01339910)
Timeframe: 18 months post-randomization
| Intervention | percentage (Number) |
|---|---|
| Myeloablative Conditioning Regimen (MAC) | 13.5 |
| Reduced Intensity Conditioning (RIC) | 48.3 |
Overall survival is defined as survival of death from any cause. (NCT01339910)
Timeframe: 18 months post-randomization
| Intervention | percentage (Number) |
|---|---|
| Myeloablative Conditioning Regimen (MAC) | 77.5 |
| Reduced Intensity Conditioning (RIC) | 67.7 |
Relapse-free survival is defined as survival without relapse of the primary disease. (NCT01339910)
Timeframe: 18 months post-randomization
| Intervention | percentage (Number) |
|---|---|
| Myeloablative Conditioning Regimen (MAC) | 67.8 |
| Reduced Intensity Conditioning (RIC) | 47.3 |
Treatment-related mortality is defined as death without a previous relapse of the primary disease. (NCT01339910)
Timeframe: 18 months post-randomization
| Intervention | percentage (Number) |
|---|---|
| Myeloablative Conditioning Regimen (MAC) | 15.8 |
| Reduced Intensity Conditioning (RIC) | 4.4 |
"Acute GVHD is graded according to the scoring system proposed by Przepiorka et al.1995:~Skin stage:~0: No rash~Rash <25% of body surface area~Rash on 25-50% of body surface area~Rash on > 50% of body surface area~Generalized erythroderma with bullous formation~Liver stage (based on bilirubin level)*:~0: <2 mg/dL~2-3 mg/dL~3.01-6 mg/dL~6.01-15.0 mg/dL~>15 mg/dL~GI stage*:~0: No diarrhea or diarrhea <500 mL/day~Diarrhea 500-999 mL/day or persistent nausea with histologic evidence of GVHD~Diarrhea 1000-1499 mL/day~Diarrhea >1500 mL/day~Severe abdominal pain with or without ileus * If multiple etiologies are listed for liver or GI, the organ system is downstaged by 1.~GVHD grade:~0: All organ stages 0 or GVHD not listed as an etiology I: Skin stage 1-2 and liver and GI stage 0 II: Skin stage 3 or liver or GI stage 1 III: Liver stage 2-3 or GI stage 2-4 IV: Skin or liver stage 4" (NCT01339910)
Timeframe: Day 100 post-transplant
| Intervention | percentage (Number) | |
|---|---|---|
| Grade II-IV Acute GVHD | Grade III-IV Acute GVHD | |
| Myeloablative Conditioning Regimen (MAC) | 44.7 | 13.6 |
| Reduced Intensity Conditioning (RIC) | 31.6 | 6.8 |
Neutrophil engraftment is defined as achieving an absolute neutrophil count greater than 500x10^6/liter for 3 consecutive measurements on different days. The first of the 3 days will be designated the day of neutrophil engraftment. Platelet engraftment is defined as achieving platelet counts greater than 20,000/microliter for consecutive measurements over 7 days without requiring platelet transfusions. The first of the 7 days will be designated the day of platelet engraftment. Subjects must not have had platelet transfusions during the preceding 7 days. (NCT01339910)
Timeframe: Days 28 and 60 post-transplant
| Intervention | percentage (Number) | |
|---|---|---|
| Neutrophil Engraftment at Day 28 | Platelet Engraftment at Day 60 | |
| Myeloablative Conditioning Regimen (MAC) | 98.5 | 95.5 |
| Reduced Intensity Conditioning (RIC) | 97.8 | 96.2 |
Donor cell engraftment will be assessed by donor-recipient chimerism assays. Full donor chimerism is defined as the presence of at least 95% donor cells as a proportion of the total population in the peripheral blood or bone marrow. Graft rejection is defined as the presence of no more than 5% donor cells as a proportion of the total population. Mixed chimerism is defined as the presence of between 5% and 95% donor cells. Mixed or full donor chimerism will be considered evidence of donor engraftment. (NCT01339910)
Timeframe: Days 28 and 100 and 18 months post-transplant
| Intervention | Participants (Count of Participants) | |||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Day 2872548419 | Day 2872548420 | Day 10072548420 | Day 10072548419 | 18 Months72548420 | 18 Months72548419 | |||||||||||||||||||||||||
| Mixed Chimerism | Full Donor Chimerism | Graft Rejection | Death Prior to Assessment | Unknown (relapsed or missing assay) | ||||||||||||||||||||||||||
| Myeloablative Conditioning Regimen (MAC) | 86 | |||||||||||||||||||||||||||||
| Reduced Intensity Conditioning (RIC) | 80 | |||||||||||||||||||||||||||||
| Myeloablative Conditioning Regimen (MAC) | 9 | |||||||||||||||||||||||||||||
| Reduced Intensity Conditioning (RIC) | 30 | |||||||||||||||||||||||||||||
| Myeloablative Conditioning Regimen (MAC) | 1 | |||||||||||||||||||||||||||||
| Myeloablative Conditioning Regimen (MAC) | 0 | |||||||||||||||||||||||||||||
| Reduced Intensity Conditioning (RIC) | 0 | |||||||||||||||||||||||||||||
| Myeloablative Conditioning Regimen (MAC) | 36 | |||||||||||||||||||||||||||||
| Reduced Intensity Conditioning (RIC) | 22 | |||||||||||||||||||||||||||||
| Myeloablative Conditioning Regimen (MAC) | 106 | |||||||||||||||||||||||||||||
| Reduced Intensity Conditioning (RIC) | 86 | |||||||||||||||||||||||||||||
| Myeloablative Conditioning Regimen (MAC) | 12 | |||||||||||||||||||||||||||||
| Myeloablative Conditioning Regimen (MAC) | 2 | |||||||||||||||||||||||||||||
| Myeloablative Conditioning Regimen (MAC) | 6 | |||||||||||||||||||||||||||||
| Reduced Intensity Conditioning (RIC) | 8 | |||||||||||||||||||||||||||||
| Myeloablative Conditioning Regimen (MAC) | 71 | |||||||||||||||||||||||||||||
| Reduced Intensity Conditioning (RIC) | 66 | |||||||||||||||||||||||||||||
| Myeloablative Conditioning Regimen (MAC) | 4 | |||||||||||||||||||||||||||||
| Reduced Intensity Conditioning (RIC) | 5 | |||||||||||||||||||||||||||||
| Reduced Intensity Conditioning (RIC) | 1 | |||||||||||||||||||||||||||||
| Myeloablative Conditioning Regimen (MAC) | 31 | |||||||||||||||||||||||||||||
| Reduced Intensity Conditioning (RIC) | 42 | |||||||||||||||||||||||||||||
| Myeloablative Conditioning Regimen (MAC) | 25 | |||||||||||||||||||||||||||||
| Reduced Intensity Conditioning (RIC) | 19 | |||||||||||||||||||||||||||||
Chronic GVHD will be defined by National Institutes of Health (NIH) criteria and requiring systemic treatment. A reduction in the cumulative incidence of GVHD from ~35% to ~15% at 1 year would represent a reasonable goal. A sample size of 42 patients provides 90% power to observe such a difference with one-side 5% type-1 error. (NCT01427881)
Timeframe: At 1 year after transplantation
| Intervention | percent of patients (Number) |
|---|---|
| Treatment (TBI, PBSCT, and Cyclophosphamide GVHD Prophylaxis) | 16 |
Disease-free survival will be evaluated as Kaplan-Meier estimates. (NCT01427881)
Timeframe: At 1 year post-transplant
| Intervention | percentage of patients (Number) |
|---|---|
| Treatment (TBI, PBSCT, and Cyclophosphamide GVHD Prophylaxis) | 73.8 |
Donor engraftment is defined as the count (percent) of patients with full donor chimerism. Full donor chimerism is defined as at least 95% donor CD3 cells in peripheral blood. (NCT01427881)
Timeframe: At day 28
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment (TBI, PBSCT, and Cyclophosphamide GVHD Prophylaxis) | 6 |
Descriptive statistics will be used to assess the incidence of primary graft failure and secondary graft failure. Primary graft failure is defined as failure to achieve a sustained neutrophil count of >= 500/uL by >= 28 days post-transplant. Secondary graft failure is defined as the decline in neutrophil count to < 500/uL after achieving engraftment which is unrelated to infection or drug effect and is unresponsive to stimulation by growth factors. (NCT01427881)
Timeframe: By greater than or equal to 28 days post-transplant
| Intervention | percentage of patients (Number) |
|---|---|
| Treatment (TBI, PBSCT, and Cyclophosphamide GVHD Prophylaxis) | 2 |
Defined as death in the absence of recurrent or progressive malignancy after HCT. Non-relapse morality will be assessed with the use of cumulative incidence plots. This secondary endpoint will be characterized and presented as a cumulative incidence. (NCT01427881)
Timeframe: At 2 years
| Intervention | percentage of patients (Number) |
|---|---|
| Treatment (TBI, PBSCT, and Cyclophosphamide GVHD Prophylaxis) | 14 |
Overall survival will be evaluated as Kaplan-Meier estimates. (NCT01427881)
Timeframe: At 1 year post-transplant
| Intervention | percentage of patients (Number) |
|---|---|
| Treatment (TBI, PBSCT, and Cyclophosphamide GVHD Prophylaxis) | 75.6 |
Recurrent or progressive malignancy will be assessed with the use of cumulative incidence plots. Recurrent malignancy will be defined by hematologic criteria. Recurrent malignancy will also be defined as any unplanned medical intervention designed to prevent progression of malignant disease in patients who have molecular, cytogenetic or flow-cytometric evidence of malignant cells after transplantation. (NCT01427881)
Timeframe: At 2 years
| Intervention | percentage of patients (Number) |
|---|---|
| Treatment (TBI, PBSCT, and Cyclophosphamide GVHD Prophylaxis) | 17 |
Grades II-IV and III-IV GVHD will be assessed with the use of cumulative incidence plots. (NCT01427881)
Timeframe: Through day +100 post-transplant
| Intervention | percentage of patients (Number) | |
|---|---|---|
| Grades II-IV GVHD | Grades III-IV GVHD | |
| Treatment (TBI, PBSCT, and Cyclophosphamide GVHD Prophylaxis) | 77 | 0 |
Descriptive statistics will be used to assess the median days of neutrophil and platelet recovery. The day of neutrophil recovery is defined as the first day of three consecutive lab values on different days, after the conditioning regimen-induced nadir of blood counts, that the absolute neutrophil count is > 500/uL. The day of platelet recovery is defined as the first day of three consecutive lab values on different days, after the conditioning regimen-induced nadir of blood counts, that the platelet count is >= 20,000/uL without platelet transfusion support in the seven days prior. (NCT01427881)
Timeframe: Up to day +100
| Intervention | days (Median) | |
|---|---|---|
| Neutrophil Engraftment | Platelet Engraftment | |
| Treatment (TBI, PBSCT, and Cyclophosphamide GVHD Prophylaxis) | 19 | 14 |
"Defined as time from date of transplant to relapse, graft rejection or graft failure, or death.~Primary non-engraftment is diagnosed when the participants fails to achieve an ANC >/= 500/ul at any time in the first 28 days post-transplant.~For participants with MDS or AML, relapse will be analyzed as to type and genetic origin of the MDS/leukemic cells. These will be defined by an increasing number of blasts in the marrow over 5% by the presence of circulating peripheral blasts, or by the presence of blasts in any extramedullary site. Cytogenetic analysis of the marrow and/or peripheral blood will also be obtained for the diagnosis of relapse." (NCT00987480)
Timeframe: 3 years
| Intervention | percentage of participants (Number) |
|---|---|
| Chemotherapy-based Cytoreductive Regimen Plus a CD34+ Selected | 77.8 |
Overall Survival is defined as time from date of transplant to event (death from any cause) or last follow-up. (NCT00987480)
Timeframe: 3 years
| Intervention | percentage of participants (Number) |
|---|---|
| Chemotherapy-based Cytoreductive Regimen Plus a CD34+ Selected | 80 |
(NCT00987480)
Timeframe: 100 days
| Intervention | percentage of participants (Number) |
|---|---|
| Chemotherapy-based Cytoreductive Regimen Plus a CD34+ Selected | 6.7 |
(NCT00987480)
Timeframe: 2 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Chemotherapy-based Cytoreductive Regimen Plus a CD34+ Selected | 0 |
Percentage of patients without relapse of disease at 2 years (NCT01991457)
Timeframe: 2 years post-transplant
| Intervention | percentage of participants (Number) |
|---|---|
| Treatment | 63.2 |
(NCT01366612)
Timeframe: 1 year
| Intervention | Percent (Number) |
|---|---|
| Group 1 | 38.9 |
| Group 2 | 18.8 |
4 reviews available for busulfan and Dysmyelopoietic Syndromes
| Article | Year |
|---|---|
Epigenetic modulation and other options to improve outcome of stem cell transplantation in MDS.
Topics: Busulfan; Combined Modality Therapy; Cyclophosphamide; Disease Progression; Drug Therapy, Combinatio | 2008 |
Treosulfan-based conditioning before hematopoietic SCT: more than a BU look-alike.
Topics: Antineoplastic Agents, Alkylating; Busulfan; Disease-Free Survival; Graft vs Host Disease; Hematopoi | 2012 |
Male predominance among Japanese adult patients with late-onset hemorrhagic cystitis after hematopoietic stem cell transplantation.
Topics: Adenoviridae Infections; Adenoviruses, Human; Adolescent; Adult; Aged; Anemia, Aplastic; BK Virus; B | 2003 |
Treatment paradigms in the management of myeloproliferative disorders.
Topics: Antineoplastic Agents, Alkylating; Busulfan; Chlorambucil; Hydroxyurea; Interferon-alpha; Leukemia, | 2004 |
69 trials available for busulfan and Dysmyelopoietic Syndromes
| Article | Year |
|---|---|
Treosulfan compared with reduced-intensity busulfan improves allogeneic hematopoietic cell transplantation outcomes of older acute myeloid leukemia and myelodysplastic syndrome patients: Final analysis of a prospective randomized trial.
Topics: Aged; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, My | 2022 |
The effect of granulocyte-colony stimulating factor, decitabine, and busulfan-cyclophosphamide versus busulfan-cyclophosphamide conditioning on relapse in patients with myelodysplastic syndrome or secondary acute myeloid leukaemia evolving from myelodyspl
Topics: Anemia, Refractory, with Excess of Blasts; Busulfan; Chronic Disease; Cyclophosphamide; Decitabine; | 2023 |
Comparative effectiveness of busulfan/cyclophosphamide versus busulfan/fludarabine myeloablative conditioning for allogeneic hematopoietic cell transplantation in acute myeloid leukemia and myelodysplastic syndrome.
Topics: Adult; Aged; Allografts; Busulfan; Cyclophosphamide; Disease-Free Survival; Female; Graft vs Host Di | 2020 |
Decitabine induction with myeloablative conditioning and allogeneic hematopoietic stem cell transplantation in high-risk patients with myeloid malignancies is associated with a high rate of infectious complications.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; De | 2020 |
Augmented Reduced-Intensity Regimen Does Not Improve Postallogeneic Transplant Outcomes in Acute Myeloid Leukemia.
Topics: Adult; Aged; Amsacrine; Busulfan; Cytarabine; Female; Graft vs Host Disease; Humans; Immunosuppressi | 2021 |
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cause of Death; Cyclosporine; | 2017 |
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cause of Death; Cyclosporine; | 2017 |
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cause of Death; Cyclosporine; | 2017 |
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cause of Death; Cyclosporine; | 2017 |
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cause of Death; Cyclosporine; | 2017 |
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cause of Death; Cyclosporine; | 2017 |
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cause of Death; Cyclosporine; | 2017 |
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cause of Death; Cyclosporine; | 2017 |
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cause of Death; Cyclosporine; | 2017 |
Dose-Reduced Versus Standard Conditioning Followed by Allogeneic Stem-Cell Transplantation for Patients With Myelodysplastic Syndrome: A Prospective Randomized Phase III Study of the EBMT (RICMAC Trial).
Topics: Adult; Busulfan; Cyclophosphamide; Dose-Response Relationship, Drug; Female; Graft vs Host Disease; | 2017 |
A Randomized Study Comparing Stem Cell Transplantation Versus Conventional Therapy for Low- and Intermediate-Risk Myelodysplastic Syndromes Patients.
Topics: Adult; Busulfan; Cyclophosphamide; Disease Progression; Factor Analysis, Statistical; Female; Graft | 2017 |
Graft-versus-Host Disease-Free, Relapse-Free Survival after Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome.
Topics: Adolescent; Adult; Aged; Allografts; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Female; | 2019 |
The incidence and risk factors of hepatic veno-occlusive disease after hematopoietic stem cell transplantation in Taiwan.
Topics: Adolescent; Adult; Allografts; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Female; Hemato | 2019 |
Conditioning regimen with a 75% dose of standard busulfan/cyclophosphamide plus fludarabine before cord blood transplantation in older patients with AML and MDS.
Topics: Aged; Allografts; Busulfan; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Disease-Free Sur | 2019 |
Cyclophosphamide followed by intravenous targeted busulfan for allogeneic hematopoietic cell transplantation: pharmacokinetics and clinical outcomes.
Topics: Adult; Aged; Busulfan; Case-Control Studies; Cyclophosphamide; Drug Administration Schedule; Hematop | 2013 |
Hematopoietic stem cell transplantation in children and young adults with secondary myelodysplastic syndrome and acute myelogenous leukemia after aplastic anemia.
Topics: Adolescent; Adult; Anemia, Aplastic; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; | 2014 |
Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia.
Topics: Adolescent; Adult; Busulfan; Child; Child, Preschool; Female; Graft vs Host Disease; Hematopoietic S | 2014 |
Extramedullary relapse following total marrow and lymphoid irradiation in patients undergoing allogeneic hematopoietic cell transplantation.
Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Agents; Blast Crisis; Bone Marrow; Busulfan; Ch | 2014 |
Results from a clofarabine-busulfan-containing, reduced-toxicity conditioning regimen prior to allogeneic stem cell transplantation: the phase 2 prospective CLORIC trial.
Topics: Adenine Nucleotides; Adult; Aged; Antilymphocyte Serum; Arabinonucleosides; Busulfan; Clofarabine; D | 2014 |
Reduced-Intensity Conditioning Combined with (188)Rhenium Radioimmunotherapy before Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia: The Role of In Vivo T Cell Depletion.
Topics: Aged; Alemtuzumab; Allografts; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, | 2015 |
Phase II Trial of Reduced-Intensity Busulfan/Clofarabine Conditioning with Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Acute Myeloid Leukemia, Myelodysplastic Syndromes, and Acute Lymphoid Leukemia.
Topics: Adenine Nucleotides; Adult; Aged; Arabinonucleosides; Busulfan; Chronic Disease; Clofarabine; Female | 2016 |
Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation.
Topics: Adolescent; Adult; Aged; Allografts; Busulfan; Child; Child, Preschool; Cyclophosphamide; Disease-Fr | 2016 |
Phase II Study of Haploidentical Natural Killer Cell Infusion for Treatment of Relapsed or Persistent Myeloid Malignancies Following Allogeneic Hematopoietic Cell Transplantation.
Topics: Adult; Busulfan; Child; Child, Preschool; Cyclophosphamide; Female; Gene Expression; Graft vs Host D | 2016 |
Toxicity and efficacy of busulfan and fludarabine myeloablative conditioning for HLA-identical sibling allogeneic hematopoietic cell transplantation in AML and MDS.
Topics: Adult; Aged; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hepatic Veno- | 2016 |
Radiation-free, alternative-donor HCT for Fanconi anemia patients: results from a prospective multi-institutional study.
Topics: Adolescent; Adult; Antilymphocyte Serum; Bone Marrow; Busulfan; Child; Child, Preschool; Cyclophosph | 2017 |
The effect of administration order of BU and CY on toxicity in hematopoietic SCT in humans.
Topics: Adolescent; Adult; Anemia, Aplastic; Busulfan; Cohort Studies; Cyclophosphamide; Follow-Up Studies; | 2009 |
Population pharmacokinetic study of a test dose oral busulfan in Japanese adult patients undergoing hematopoietic stem cell transplantation.
Topics: Administration, Oral; Adolescent; Adult; Aged; Algorithms; Antineoplastic Agents, Alkylating; Area U | 2010 |
Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies.
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined | 2011 |
Myeloablative reduced-toxicity i.v. busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth decades of life.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Disease-Free Survival | 2011 |
Clinical effect of reduced-intensity conditioning regimen containing antithymocyte globulin for hematopoietic cell transplantation from unrelated-donors.
Topics: Adolescent; Adult; Antilymphocyte Serum; Antineoplastic Agents; Bone Marrow Transplantation; Busulfa | 2011 |
Reduced-toxicity conditioning with treosulfan and fludarabine in allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes: final results of an international prospective phase II trial.
Topics: Adult; Antineoplastic Agents; Busulfan; Chimerism; Female; Graft vs Host Disease; Hematopoietic Stem | 2011 |
Upfront allogeneic blood stem cell transplantation for patients with high-risk myelodysplastic syndrome or secondary acute myeloid leukemia using a FLAMSA-based high-dose sequential conditioning regimen.
Topics: Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; | 2012 |
Allo-SCT for AML and MDS with treosulfan compared with BU-based regimens: reduced toxicity vs reduced intensity.
Topics: Adult; Aged; Busulfan; Disease-Free Survival; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, | 2012 |
Randomized trial of myeloablative conditioning regimens: busulfan plus cyclophosphamide versus busulfan plus fludarabine.
Topics: Adolescent; Adult; Aged; Busulfan; Cyclophosphamide; Drug Therapy, Combination; Female; Gastroenteri | 2013 |
Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome.
Topics: Adolescent; Adult; Bone Marrow Cells; Busulfan; Child; Cyclophosphamide; Cytogenetic Analysis; Disea | 2002 |
Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Follow-Up Studies; Gr | 2002 |
Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Female; Fo | 2003 |
Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality | 2003 |
Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation.
Topics: Acute Disease; Adult; Aged; Alkylating Agents; Busulfan; Chronic Disease; Family; Female; Histocompa | 2004 |
Lack of cytoprotective effect of amifostine following HLA-identical sibling transplantation for advanced myelodysplastic syndrome (MDS): a pilot study.
Topics: Adult; Amifostine; Busulfan; Cause of Death; Cytoprotection; Hematopoietic Stem Cell Transplantation | 2003 |
Reduced-intensity stem cell transplantation from an HLA-identical sibling donor in patients with myeloid malignancies.
Topics: Adult; Aged; Antilymphocyte Serum; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Busulfa | 2004 |
Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning.
Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neo | 2004 |
Treosulfan/fludarabine: a new conditioning regimen in allogeneic transplantation.
Topics: Busulfan; Humans; Leukemia; Leukemia, Myeloid, Acute; Leukocyte Transfusion; Lymphoma; Myelodysplast | 2004 |
Targeted busulfan and cyclophosphamide as compared to busulfan and TBI as preparative regimens for transplantation in patients with advanced MDS or transformation to AML.
Topics: Adolescent; Adult; Aged; Busulfan; Child; Child, Preschool; Cyclophosphamide; Female; Graft Rejectio | 2004 |
Comparison of 2 preparative regimens for stem cell transplantation from HLA-matched sibling donors in patients with advanced myelodysplastic syndrome.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Alkylating; Busulfan; Cyclophosphami | 2005 |
Population pharmacokinetics of intravenous busulfan in patients undergoing hematopoietic stem cell transplantation.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Body Fluid Compartments; Body Mas | 2006 |
Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS).
Topics: Acute Disease; Adult; Aged; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Bu | 2006 |
Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Cause of Death; Child; Chron | 2006 |
Outcomes of alemtuzumab-based reduced intensity conditioning stem cell transplantation using unrelated donors for myelodysplastic syndromes.
Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neo | 2006 |
Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) stem cell transplantation using nonmyeloablative conditioning.
Topics: Adult; Antilymphocyte Serum; Bone Marrow; Busulfan; CD4 Lymphocyte Count; Combined Modality Therapy; | 2006 |
Pharmacokinetics of once-daily IV busulfan as part of pretransplantation preparative regimens: a comparison with an every 6-hour dosing schedule.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Aged; Area Under Curve; Busulfan; Drug Admin | 2007 |
Intravenous busulfan and melphalan, tacrolimus, and short-course methotrexate followed by unmodified HLA-matched related or unrelated hematopoietic stem cell transplantation for the treatment of advanced hematologic malignancies.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool | 2007 |
The beneficial effect of chronic graft-versus-host disease on the clinical outcome of transplantation with fludarabine/busulfan-based reduced-intensity conditioning for patients with de novo myelodysplastic syndrome.
Topics: Adolescent; Adult; Antineoplastic Agents; Busulfan; Chronic Disease; Female; Follow-Up Studies; Graf | 2007 |
Prospective phase II trial to evaluate the complications and kinetics of chimerism induction following allogeneic hematopoietic stem cell transplantation with fludarabine and busulfan.
Topics: Adult; Aged; Busulfan; Cyclosporine; Drug Therapy, Combination; Female; Graft Survival; Graft vs Hos | 2007 |
Fludarabine/i.v. BU conditioning regimen: myeloablative, reduced intensity or both?
Topics: Adolescent; Adult; Bone Marrow Transplantation; Busulfan; Disease-Free Survival; Drug Therapy, Combi | 2008 |
Reduced-intensity conditioning allogeneic transplantation from unrelated donors: evaluation of mycophenolate mofetil plus cyclosporin A as graft-versus-host disease prophylaxis.
Topics: Adolescent; Adult; Antineoplastic Agents; Bone Marrow Transplantation; Busulfan; Combined Modality T | 2008 |
Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS.
Topics: Adolescent; Adult; Antilymphocyte Serum; Antineoplastic Agents; Bayes Theorem; Busulfan; Combined Mo | 2008 |
In stem cell transplantation, by limiting the morbidity of graft-versus-host disease tolerance to myeloablative conditioning is improved.
Topics: Adolescent; Adult; Alemtuzumab; Antibiotic Prophylaxis; Antibodies, Monoclonal; Antibodies, Monoclon | 2008 |
Intensified conditioning regimen with busulfan followed by allogeneic BMT in children with myelodysplastic syndromes.
Topics: Anemia, Refractory; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Combined Modalit | 1994 |
A phase I-II study of high-dose thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic marrow transplantation.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busu | 1994 |
A randomized trial comparing busulfan vs total body irradiation in allogeneic marrow transplant recipients with hematological malignancies.
Topics: Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Humans; Immunosuppression Therapy; Leukemia | 1994 |
Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: a phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors.
Topics: Adolescent; Adult; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow | 1996 |
Toxicity of busulfan and cyclophosphamide (BU/CY2) in patients with hematologic malignancies.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Bone Marrow Transplantation; Busulfan; Combine | 1996 |
Bone marrow engraftment following unrelated donor transplantation utilizing busulfan and cyclophosphamide preparatory chemotherapy.
Topics: Acute Disease; Adolescent; Adult; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Ch | 1996 |
Therapeutic trial of intensified conditioning regimen with high-dose cytosine arabinoside, cyclophosphamide and either total body irradiation or busulfan followed by allogeneic bone marrow transplantation for myelodysplastic syndrome in children.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Child; Child, | 1997 |
A prospective study of autologous bone marrow or peripheral blood stem cell transplantation after intensive chemotherapy in myelodysplastic syndromes. Groupe Français des Myélodysplasies. Group Ouest-Est d'étude des Leucémies aiguës myéloïdes.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation | 1999 |
Hematopoietic stem cell transplantation for childhood myeloid malignancies after high-dose thiotepa, busulfan and cyclophosphamide.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Combi | 1999 |
Analysis of prognostic factors for allogeneic marrow transplantation following busulfan and cyclophosphamide in myelodysplastic syndrome and after leukemic transformation.
Topics: Adult; Antineoplastic Agents, Alkylating; Bone Marrow Transplantation; Busulfan; Child; Combined Mod | 2000 |
Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Busul | 2000 |
Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia.
Topics: Adolescent; Adult; Anemia, Refractory, with Excess of Blasts; Antineoplastic Agents, Alkylating; Bon | 2001 |
Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome after conditioning with busulfan and fractionated total body irradiation is associated with low relapse rate but considerable nonrelapse mortality.
Topics: Adolescent; Adult; Busulfan; Cause of Death; Child; Female; Humans; Male; Middle Aged; Myelodysplast | 2002 |
Therapeutic potential of a reduced-intensity preparative regimen for allogeneic transplantation with cladribine, busulfan, and antithymocyte globulin against advanced/refractory acute leukemia/lymphoma.
Topics: Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Cladribine; Combined Modality Therapy; Graf | 2002 |
103 other studies available for busulfan and Dysmyelopoietic Syndromes
| Article | Year |
|---|---|
Fludarabine/busulfan versus busulfan/cyclophosphamide as myeloablative conditioning for myelodysplastic syndrome: a propensity score-matched analysis.
Topics: Busulfan; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; | 2021 |
Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome using treosulfan based compared to other reduced-intensity or myeloablative conditioning regimens. A report of the chronic malignancies working party of the EBMT.
Topics: Adolescent; Adult; Aged; Allografts; Busulfan; Cyclophosphamide; Disease Progression; Female; Follow | 2021 |
Combination of treosulfan, fludarabine and cytarabine as conditioning in patients with acute myeloid leukemia, myelodysplastic syndrome and myeloproliferative neoplasms.
Topics: Busulfan; Cytarabine; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukem | 2022 |
Myeloablative Versus Reduced-Intensity Conditioning With Fludarabine/Busulfan for Myelodysplastic Syndrome: A Propensity Score-Matched Analysis.
Topics: Adult; Busulfan; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplast | 2022 |
Comparison of Pulmonary Toxicity after Total Body Irradiation- and Busulfan-Based Myeloablative Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Patients.
Topics: Busulfan; Child; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; M | 2022 |
Busulfan, fludarabine, and melphalan are effective conditioning for pediatric and young adult patients with myeloid malignancies underdoing matched sibling or alternative donor transplantation.
Topics: Adolescent; Busulfan; Child; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; | 2023 |
Busulfan, fludarabine, and melphalan are effective conditioning for pediatric and young adult patients with myeloid malignancies underdoing matched sibling or alternative donor transplantation.
Topics: Adolescent; Busulfan; Child; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; | 2023 |
Busulfan, fludarabine, and melphalan are effective conditioning for pediatric and young adult patients with myeloid malignancies underdoing matched sibling or alternative donor transplantation.
Topics: Adolescent; Busulfan; Child; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; | 2023 |
Busulfan, fludarabine, and melphalan are effective conditioning for pediatric and young adult patients with myeloid malignancies underdoing matched sibling or alternative donor transplantation.
Topics: Adolescent; Busulfan; Child; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; | 2023 |
Busulfan, fludarabine, and melphalan are effective conditioning for pediatric and young adult patients with myeloid malignancies underdoing matched sibling or alternative donor transplantation.
Topics: Adolescent; Busulfan; Child; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; | 2023 |
Busulfan, fludarabine, and melphalan are effective conditioning for pediatric and young adult patients with myeloid malignancies underdoing matched sibling or alternative donor transplantation.
Topics: Adolescent; Busulfan; Child; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; | 2023 |
Busulfan, fludarabine, and melphalan are effective conditioning for pediatric and young adult patients with myeloid malignancies underdoing matched sibling or alternative donor transplantation.
Topics: Adolescent; Busulfan; Child; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; | 2023 |
Busulfan, fludarabine, and melphalan are effective conditioning for pediatric and young adult patients with myeloid malignancies underdoing matched sibling or alternative donor transplantation.
Topics: Adolescent; Busulfan; Child; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; | 2023 |
Busulfan, fludarabine, and melphalan are effective conditioning for pediatric and young adult patients with myeloid malignancies underdoing matched sibling or alternative donor transplantation.
Topics: Adolescent; Busulfan; Child; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; | 2023 |
Treosulfan, thiotepa and fludarabine conditioning regimen prior to first allogeneic stem cell transplantation in acute myeloid leukemia and high-risk myelodysplastic syndromes: a single center experience.
Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, | 2023 |
Myeloablative Dose of Busulfan and Fludarabine Combined with In Vivo T Cell Depletion Is Safe and Effective Conditioning for Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients.
Topics: Busulfan; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Synd | 2023 |
A New Conditioning Regimen Can Significantly Promote Post-Transplant Immune Reconstitution and Improve the Outcome of Umbilical Cord Blood Transplantation for Patients.
Topics: Adult; Anemia, Aplastic; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busul | 2019 |
Conditioning Regimen of 5-Day Decitabine Administration for Allogeneic Stem Cell Transplantation in Patients with Myelodysplastic Syndrome and Myeloproliferative Neoplasms.
Topics: Busulfan; Decitabine; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukem | 2020 |
Comparison of non-myeloablative and reduced-intensity allogeneic stem cell transplantation in older patients with myelodysplastic syndromes.
Topics: Age Factors; Aged; Aged, 80 and over; Busulfan; Comorbidity; Graft vs Host Disease; Humans; Immunosu | 2019 |
Comparison of melphalan- And busulfan-based myeloablative conditioning in children undergoing allogeneic transplantation for acute myeloid leukemia or myelodysplasia.
Topics: Adolescent; Busulfan; Child; Child, Preschool; Female; Hematopoietic Stem Cell Transplantation; Huma | 2020 |
Improved Outcomes after Allogenic Hematopoietic Stem Cell Transplantation with Fludarabine/Treosulfan for Patients with Myelodysplastic Syndromes.
Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Myelodysplastic Sy | 2020 |
Myeloablative intravenous busulfan-containing regimens for allo-HSCT in AML or MDS patients over 54 years old: combined results of three phase II studies.
Topics: Age Factors; Aged; Busulfan; Clinical Trials, Phase II as Topic; Disease-Free Survival; Female; Hema | 2020 |
Decitabine prior to salvaged cord blood transplantation for acute myeloid leukaemia/myelodysplastic syndrome not in remission.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool | 2020 |
Fractionated busulfan myeloablative conditioning improves survival in older patients with acute myeloid leukemia and myelodysplastic syndrome.
Topics: Aged; Busulfan; Humans; Leukemia, Myeloid, Acute; Myeloablative Agonists; Myelodysplastic Syndromes; | 2021 |
Leukemia after gene therapy for sickle cell disease: insertional mutagenesis, busulfan, both, or neither.
Topics: Alkylating Agents; Anemia, Sickle Cell; Busulfan; Clinical Trials as Topic; Gene Editing; Genetic Th | 2021 |
Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improve Transplantation Outcomes in Older Patients with Myelodysplastic Syndromes.
Topics: Aged; Busulfan; Graft vs Host Disease; Humans; Melphalan; Middle Aged; Myelodysplastic Syndromes; Su | 2021 |
Missing HLA C group 1 ligand in patients with AML and MDS is associated with reduced risk of relapse and better survival after allogeneic stem cell transplantation with fludarabine and treosulfan reduced toxicity conditioning.
Topics: Adult; Aged; Busulfan; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Genotype; He | 2017 |
A Chemotherapy-Only Regimen of Busulfan, Melphalan, and Fludarabine, and Rabbit Antithymocyte Globulin Followed by Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplantations for the Treatment of Myeloid Malignancies.
Topics: Adolescent; Adult; Aged; Animals; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protoco | 2017 |
Comparison of Conditioning with Fludarabine/Busulfan and Fludarabine/Melphalan in Allogeneic Transplantation Recipients 50 Years or Older.
Topics: Aged; Aged, 80 and over; Busulfan; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid, Acu | 2017 |
Transformation of MDS/MPN-RS-T to AML: Trisomy 13, resistant thrombocytosis and transient disease control with oral busulfan therapy.
Topics: Anemia, Sideroblastic; Busulfan; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Thromb | 2018 |
A Comparison of the Myeloablative Conditioning Regimen Fludarabine/Busulfan with Cyclophosphamide/Total Body Irradiation, for Allogeneic Stem Cell Transplantation in the Modern Era: A Cohort Analysis.
Topics: Adult; Aged; Busulfan; Cohort Studies; Cyclophosphamide; Female; Graft vs Host Disease; Hematologic | 2018 |
Pharmacokinetics-adapted Busulfan-based myeloablative conditioning before unrelated umbilical cord blood transplantation for myeloid malignancies in children.
Topics: Adolescent; Busulfan; Child; Child, Preschool; Cord Blood Stem Cell Transplantation; Cyclophosphamid | 2018 |
Busulfan-based myeloablative conditioning regimens for haploidentical transplantation in high-risk acute leukemias and myelodysplastic syndromes.
Topics: Adolescent; Adult; Aged; Busulfan; Combined Modality Therapy; Female; Graft vs Host Disease; Hematop | 2018 |
Fludarabine and busulfan plus low-dose TBI as reduced intensity conditioning in older patients undergoing allogeneic hematopoietic cell transplant for myeloid malignancies.
Topics: Aged; Aged, 80 and over; Allografts; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combi | 2018 |
Reduced intensity vs. myeloablative conditioning with fludarabine and PK-guided busulfan in allogeneic stem cell transplantation for patients with AML/MDS.
Topics: Antineoplastic Agents, Alkylating; Busulfan; Female; Hematopoietic Stem Cell Transplantation; Humans | 2019 |
[Decitabine-based conditioning regimen is feasible and effective in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia].
Topics: Adult; Busulfan; Decitabine; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; | 2019 |
Increased risk of gastrointestinal acute GVHD following the addition of melphalan to busulfan/cyclophosphamide conditioning.
Topics: Adolescent; Busulfan; Child; Child, Preschool; Cyclophosphamide; Female; Gastrointestinal Tract; Gra | 2013 |
Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.
Topics: Aged; Busulfan; Female; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; | 2013 |
Reduced-intensity conditioning therapy with fludarabine, idarubicin, busulfan and cytarabine for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia and myelodysplastic syndrome.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool | 2013 |
Feasible outcomes of T cell-replete haploidentical stem cell transplantation with reduced-intensity conditioning in patients with myelodysplastic syndrome.
Topics: Acute Disease; Adult; Aged; Antilymphocyte Serum; Busulfan; Chronic Disease; Female; Graft vs Host D | 2015 |
[Combination of busulfan with increased-dose of fludarabine as conditioning regimen for MDS and MDS-AML patients with allo-HSCT].
Topics: Busulfan; Disease-Free Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hum | 2015 |
Mixed T Lymphocyte Chimerism after Allogeneic Hematopoietic Transplantation Is Predictive for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Topics: Adult; Busulfan; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantat | 2015 |
HLA haploidentical peripheral blood stem cell transplantation using reduced dose of posttransplantation cyclophosphamide for poor-prognosis or refractory leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Busulfan; Cyclophosphamide; Disease-Free Survival; Female; G | 2015 |
Subacute hepatic necrosis mimicking veno-occlusive disease in a patient with HFE H63D homozygosity after allogeneic hematopoietic cell transplantation with busulfan conditioning.
Topics: Acute Disease; Adult; Allografts; Busulfan; Diagnosis, Differential; Hematopoietic Stem Cell Transpl | 2015 |
Impact of Thymoglobulin by Stem Cell Source (Peripheral Blood Stem Cell or Bone Marrow) After Myeloablative Stem Cell Transplantation From HLA 10/10-Matched Unrelated Donors: A Report From the Société Française de Greffe de Moelle et de Thérapie Cellulair
Topics: Adolescent; Adult; Antilymphocyte Serum; Bone Marrow Transplantation; Busulfan; Chi-Square Distribut | 2016 |
The efficacy and safety of a new reduced-toxicity conditioning with 4 days of once-daily 100 mg/m(2) intravenous busulfan associated with fludarabine and antithymocyte globulins prior to allogeneic stem cell transplantation in patients with high-risk myel
Topics: Adult; Aged; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Comorbi | 2016 |
Non-myeloablative conditioning for lower-risk myelodysplastic syndrome with bone marrow blasts less than 5 %-a feasibility study.
Topics: Adolescent; Adult; Antilymphocyte Serum; Bone Marrow Cells; Busulfan; Cyclophosphamide; Feasibility | 2016 |
Fludarabine-Busulfan Reduced-Intensity Conditioning in Comparison with Fludarabine-Melphalan Is Associated with Increased Relapse Risk In Spite of Pharmacokinetic Dosing.
Topics: Adolescent; Adult; Aged; Area Under Curve; Busulfan; Female; Humans; Karnofsky Performance Status; L | 2016 |
Long-Term Outcomes after Treatment with Clofarabine ± Fludarabine with Once-Daily Intravenous Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and Myelodysplastic Syndrome.
Topics: Adenine Nucleotides; Adolescent; Adult; Arabinonucleosides; Busulfan; Child; Clofarabine; Female; Gr | 2016 |
Comparative Effectiveness of Busulfan and Fludarabine versus Fludarabine and 400 cGy Total Body Irradiation Conditioning Regimens for Acute Myeloid Leukemia/Myelodysplastic Syndrome.
Topics: Adult; Aged; Busulfan; Erythrocyte Transfusion; Female; Graft vs Host Disease; Humans; Leukemia, Mye | 2017 |
Outcomes of children, adolescents, and young adults following allogeneic stem cell transplantation for secondary acute myeloid leukemia and myelodysplastic syndromes-The MD Anderson Cancer Center experience.
Topics: Adolescent; Adult; Busulfan; Child; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplan | 2017 |
Evaluating pharmacokinetics and pharmacodynamics of intravenous busulfan in pediatric patients receiving bone marrow transplantation.
Topics: Adolescent; Area Under Curve; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Female | 2009 |
Comparative analysis of BU and CY versus CY and TBI in full intensity unrelated marrow donor transplantation for AML, CML and myelodysplasia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busu | 2011 |
Long term follow-up of allogeneic stem cell transplantation in patients with myelodysplastic syndromes using busulfan, cytosine arabinoside, and cyclophosphamide.
Topics: Adolescent; Adult; Aged; Busulfan; Cyclophosphamide; Cytarabine; Disease-Free Survival; Female; Foll | 2010 |
Retrospective analysis of treosulfan-based conditioning in comparison with standard conditioning in patients with myelodysplastic syndrome.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Busulfan; Comorbidity; Disease-Free Surv | 2011 |
Allogeneic hematopoietic stem cell transplant after intravenous busulfan and fludarabine conditioning.
Topics: Adult; Aged; Antineoplastic Agents; Busulfan; Female; Hematopoietic Stem Cell Transplantation; Human | 2011 |
Deferasirox increases BU blood concentrations.
Topics: Benzoates; Busulfan; Deferasirox; Female; Humans; Immunosuppressive Agents; Iron Chelating Agents; M | 2012 |
Single center retrospective analysis of BU-based conditioning regimens in allogeneic transplantation.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Hematopoi | 2012 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Femal | 2011 |
Long-term salivary function after conditioning with busulfan, fractionated or single-dose TBI.
Topics: Adolescent; Age Factors; Anemia, Aplastic; Area Under Curve; Busulfan; Cyclophosphamide; Dose Fracti | 2011 |
Intravenous compared with oral busulfan as preparation for allogeneic hematopoietic progenitor cell transplantation for AML and MDS.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; | 2012 |
Outcome of allogeneic stem cell transplantation with a conditioning regimen of busulfan, cyclophosphamide and low-dose etoposide for children with myelodysplastic syndrome.
Topics: Adolescent; Busulfan; Child; Child, Preschool; Cyclophosphamide; Dose-Response Relationship, Drug; E | 2011 |
Primary adrenal insufficiency in a child after busulfan and cyclophosphamide-based conditioning for hematopoietic stem cell transplantation.
Topics: Addison Disease; Busulfan; Child; Cyclophosphamide; Female; Hematopoietic Stem Cell Transplantation; | 2011 |
The increase from 2.5 to 5 mg/kg of rabbit anti-thymocyte-globulin dose in reduced intensity conditioning reduces acute and chronic GVHD for patients with myeloid malignancies undergoing allo-SCT.
Topics: Adolescent; Adult; Aged; Animals; Antilymphocyte Serum; Busulfan; Graft vs Host Disease; Hematopoiet | 2012 |
Hierarchical Bayesian approaches to phase II trials in diseases with multiple subtypes.
Topics: Antineoplastic Agents; Bayes Theorem; Benzamides; Bone Marrow Transplantation; Busulfan; Clinical Tr | 2003 |
Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan.
Topics: Acute Disease; Alkylating Agents; Busulfan; Chronic Disease; Drug Therapy, Combination; Female; Huma | 2003 |
Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS.
Topics: Adult; Aged; Busulfan; Female; Graft vs Host Disease; Histocompatibility Testing; Humans; Immunosupp | 2004 |
Reduced intensity conditioning compared to standard conditioning preserves the in vitro growth capacity of bone marrow stroma, which remains of host origin.
Topics: Adult; Aged; Anemia, Aplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Bo | 2005 |
Effect of conditioning regimen on the outcome of bone marrow transplantation from an unrelated donor.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Cyclophosphamid | 2005 |
[Study on unrelated donor allogeneic bone marrow transplantation with Bu-CY2 conditioning regimen for myelodysplastic syndrome].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busu | 2006 |
Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adult; Aged; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Female; Graft S | 2006 |
Long-term outcome of Hodgkin disease patients following high-dose busulfan, etoposide, cyclophosphamide, and autologous stem cell transplantation.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality | 2006 |
Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic d
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Pre | 2007 |
Fludarabine and treosulfan: a novel modified myeloablative regimen for allogeneic hematopoietic stem-cell transplantation with effective antileukemia activity in patients with acute myeloid leukemia and myelodysplastic syndromes.
Topics: Adult; Aged; Busulfan; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Human | 2007 |
Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
Topics: Adult; Aged; Busulfan; Chronic Disease; Disease-Free Survival; Drug Therapy, Combination; Female; Gr | 2008 |
Early recovery of host-derived hematopoiesis in marrow transplant recipients conditioned with high-dose busulfan and cyclophosphamide.
Topics: Adolescent; Bone Marrow Transplantation; Busulfan; Child, Preschool; Combined Modality Therapy; Cycl | 1995 |
Unrelated bone marrow donor transplants for children with leukemia or myelodysplasia.
Topics: Actuarial Analysis; Adolescent; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cycl | 1995 |
Survival after ABO-incompatible allogeneic bone marrow transplant after a preparative regimen of busulfan and cyclophosphamide.
Topics: ABO Blood-Group System; Adult; Blood Group Incompatibility; Bone Marrow Transplantation; Busulfan; C | 1995 |
Graft failure in children receiving HLA-mismatched marrow transplants with busulfan-containing regimens.
Topics: Adolescent; Adult; Age Factors; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Comb | 1994 |
Eosinophilia after allogeneic bone marrow transplantation using the busulfan and cyclophosphamide preparative regimen.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Busulfan; Chronic Disease; Cyclophosphamide; Eosinop | 1994 |
Busulfan, cyclophosphamide and melphalan as conditioning regimen for bone marrow transplantation in children with myelodysplastic syndromes.
Topics: Adolescent; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocol | 1994 |
Acute graft-versus-host disease prophylaxis with methotrexate and cyclosporine after busulfan and cyclophosphamide in patients with hematologic malignancies.
Topics: Adult; Busulfan; Chronic Disease; Combined Modality Therapy; Cyclophosphamide; Cyclosporine; Female; | 1993 |
Busulfan-based regimens and allogeneic bone marrow transplantation in patients with myelodysplastic syndromes.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Chromosome Aberra | 1993 |
Busulfan/cyclophosphamide as conditioning regimen for allogeneic bone marrow transplantation for myelodysplasia.
Topics: Adolescent; Adult; Aged; Bone Marrow Purging; Bone Marrow Transplantation; Busulfan; Child; Child, P | 1995 |
Derivative (y)t(Y;1)(q12;q12),+9 in a patient with polycythemia vera during transition into myelodysplasia.
Topics: Bone Marrow; Busulfan; Chromosome Aberrations; Chromosomes, Human, Pair 1; Humans; In Situ Hybridiza | 1996 |
Factors influencing outcome in de novo myelodysplastic syndromes treated by allogeneic bone marrow transplantation: a long-term study of 71 patients Société Française de Greffe de Moelle.
Topics: Adult; Anemia, Refractory; Anemia, Refractory, with Excess of Blasts; Bone Marrow Transplantation; B | 1996 |
Unrelated allogeneic bone marrow transplantation using high-dose busulfan and cyclophosphamide (BU-CY) for the preparative regimen.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols | 1996 |
Detection of occasional and clonal chromosome aberrations in patients with acute non-lymphocytic leukemia after autologous bone marrow transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Bone Marrow Transplantation; Bu | 1996 |
Abnormal thyroid stimulating hormone (TSH) levels in adults following allogeneic bone marrow transplants.
Topics: Adolescent; Adult; Anemia, Aplastic; Antineoplastic Combined Chemotherapy Protocols; Autoimmune Dise | 1997 |
Busulfan/cyclophosphamide in volunteer unrelated donor (VUD) BMT: excellent feasibility and low incidence of treatment-related toxicity.
Topics: Adult; Antilymphocyte Serum; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Cyclosporine; | 1997 |
Is hydroxyurea leukemogenic in essential thrombocythemia?
Topics: Acute Disease; Antineoplastic Agents, Alkylating; Bone Marrow; Busulfan; Chromosome Aberrations; Chr | 1998 |
Bone marrow transplantation in pediatric patients with therapy-related myelodysplasia and leukemia.
Topics: Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyclophosphamide; Female; Graft Surv | 1999 |
Leukemia and myelodysplasia in patients with essential thrombocythemia treated with cytotoxic agents.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Busulfan; Female; Follow-Up Studies; Humans; | 1999 |
Leukemia and myelodysplasia effect of multiple cytotoxic therapy in essential thrombocythemia.
Topics: Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Busulfan; Fatal Outcome; Female; Humans; Hydro | 2000 |
Allogeneic stem cell transplantation (BMT) for AML and MDS following i.v. busulfan and cyclophosphamide (i.v. BuCy).
Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophospham | 2000 |
Total body irradiation before allogeneic bone marrow transplantation: is more dose better?
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busu | 2001 |
Hematopoietic stem-cell transplantation for treatment-related leukemia or myelodysplasia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Disease-Free Surv | 2001 |
The pharmacodynamic effect of busulfan in the P39 myeloid cell line in vitro.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Busulfan; Humans; Leukocytes; Myelodysplastic Syndrome | 2001 |
Intravenous busulphan for conditioning before autologous or allogeneic human blood stem cell transplantation.
Topics: Acute Disease; Adolescent; Adult; Area Under Curve; Busulfan; Drug Administration Schedule; Female; | 2001 |
A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome.
Topics: Adult; Anemia, Refractory, with Excess of Blasts; Antilymphocyte Serum; Bone Marrow; Busulfan; Cell | 2001 |
Pharmacokinetics of intravenous busulfan in children prior to stem cell transplantation.
Topics: Adolescent; Area Under Curve; Bayes Theorem; Busulfan; Child; Child, Preschool; Half-Life; Hematopoi | 2002 |
Treatment of myelodysplastic syndrome with busulfan-cyclophosphamide conditioning followed by allogeneic BMT.
Topics: Acute Disease; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Trans | 1992 |
Allogeneic bone marrow transplantation in high-risk myeloid disorders using busulfan, cytosine arabinoside and cyclophosphamide (BAC).
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busu | 1992 |
More on high-dose busulfan and seizure prophylaxis.
Topics: Adult; Bone Marrow Purging; Bone Marrow Transplantation; Busulfan; Epilepsy; Female; Humans; Leukemi | 1992 |
Influence of immunosuppression on acute liver toxicity after intensified conditioning regimens for bone marrow transplantation in children.
Topics: Bone Marrow Transplantation; Busulfan; Child; Cyclosporins; Drug Therapy, Combination; Etoposide; Gr | 1991 |
Bestatin treatment of myelodysplastic syndromes and chronic myelogenous leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Busulfan; Drug Therapy, Combination; Fe | 1991 |
Bone marrow transplantation for patients with myelodysplasia. Pretreatment variables and outcome.
Topics: Adolescent; Adult; Age Factors; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Comb | 1990 |
[Polycythemia vera terminating in myelodysplastic syndrome].
Topics: Aged; Busulfan; Carbazilquinone; Humans; Male; Myelodysplastic Syndromes; Polycythemia Vera | 1990 |
Marrow aplasia developing 3 years after treatment with busulphan for chronic myeloid leukaemia.
Topics: Adult; Busulfan; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myelogenous, Chr | 1989 |
Marrow transplantation for patients with severe myelodysplasia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Combined Moda | 1989 |
8;21 translocation in myelodysplasia secondary to essential thrombocythemia.
Topics: Aged; Busulfan; Cell Transformation, Neoplastic; Cytogenetics; Female; Humans; Karyotyping; Leukemia | 1989 |